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 ABSTRACT 
 
An investigation has been conducted into factors affecting the inter-
particulate cohesion profile of three micronised drugs, as a function of 
humidity. An atomic force microscope (AFM) colloid probe technique was 
correlated with physico-chemical properties and in-vitro performance.  
 
Briefly, micronised drug particles of salbutamol sulphate, triamcinolone 
acetonide (TAA) and disodium cromoglycate (DSCG) were mounted onto V-
shaped tipless cantilevers using a developed micromanipulation technique. 
Interactions between the AFM ‘drug probes’ and a series of model drug 
surfaces were conducted at a 15,30, 45, 60 and 75% relative humidity using 
a custom built perfusion apparatus connected to the AFM. 
 
As expected, separation energy distributions for drug probe interactions were 
dependent on the surface rugosity of the drug model surfaces. Separation 
energy measurements conducted between drug probes and individual 
micronised drug particles (mounted in polymer resin) suggested large 
variations in separation energy. Further analysis of such data suggested a 
lognormal separation energy distribution, however, limitations in individual 
particle measurements (finite particle measurements per experiment) allowed 
restricted statistical analysis.  
 
Construction of large planar model drug surfaces (>100µm) allowed the 
collection of large data sets (~4096) over relatively large areas (~10µm), thus 
allowing a more complete distribution analysis. Drug probe separation energy 
interactions with compacted drug surfaces, indicated a lognormal distribution, 
most likely attributed to the variation in particle surface contact geometry. 
Conducting separation energy measurements between drug probes and 
‘atomically smooth’ crystals, prepared via controlled crystallisation, further 
substantiated such observations, as normal separation energy distributions 
were observed (relating to low variation in particle crystal contact geometry). 
 
 Relative humidity had a statistically significant influence on the separation 
energy (cohesion) of all three micronised drugs. The separation energy for 
salbutamol sulphate and DSCG increased as humidity was raised, while the 
separation energy for TAA decreased. Variations in the humidity-cohesion 
profile for the three drugs were attributed to the chemical and physical 
properties of each specific drug.  
 
To corroborate such observations, a series of bulk analysis techniques and 
in-vitro particle aerosolisation studies were conducted. The AFM separation 
energy cohesion profile correlated well with both the bulk moisture sorption 
and the fine particle fraction of aerosolised drug particles. 
 
The AFM colloid probe technique has successfully been developed to allow 
the measurement of micronised particle interactions specific to inhalation 
technology. Furthermore such correlation between bulk and in-vitro 
behaviour, as a function of environmental conditions, may allow rapid 
screening of drugs during the formulation process.    
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1.1 DELIVERY OF DRUGS TO THE RESPIRATORY TRACT. 
 
The delivery of pharmaceutical agents to the respiratory tract via the 
inhalation route has become an integral part of drug therapy. The advantages 
of pulmonary delivery are well recognised.  Smaller therapeutic doses are 
required, the surface area of the lung is large (around 100 m2, Patton 1996), 
and the delivery system allows rapid molecule transfer across cell 
membranes while avoiding first pass gastric metabolism (Timsina et al 1994).   
 
In simple terms, the structure of the lung consists of a series of branching 
airways (Figure 1.1.1) starting at the trachea and decreasing in size through 
more than 17 bifurcations to terminate in the alveolar sacks (Patton 1996).  
Transfer of oxygen, carbon dioxide and macromolecules occur mainly 
through the alveolar, whose structure comprises of an endothelial capillary 
system surrounded by epithelial cells (which are coated with a surface fluid 
and surfactant layer).  The whole structure is bound by intracellular fibres and 
is able to expand and contract during inhalation. 
 
When delivered efficiently, a dose targeting at least twenty times less than 
that required for oral administration can be easily achieved with equivalent 
results and reduced side effects (Ganderton and Kassem 1992). However, 
the delivery of pharmaceutical agents via the inhalation route is restricted by 
the natural defence mechanism that is the upper airways.  Impaction and 
sedimentation act as major forms of particulate entrapment, preventing 
ingress of natural airborne hazards (including pharmaceutical compounds) 
into sensitive regions of the lung. To circumvent such an effective defence 
mechanism, drug particulates need to possess minimal ballistic effect (to limit 
impaction), while maintaining a high velocity (to limit residence time and 





Figure 1.1.1 Diagrammatic representation of the human tracheal system 
(modified from Florence and Attwood, 1998). 
 
The minimisation of impaction and sedimentation in the respiratory tract is 
not a complicated procedure. Simply put, a reduction in mass or density of 
the entrained particles will cause a reduction in the imparted forces. Such a 
reduction would clearly cause both a decreases in inertia (allowing particles 
to remain entrained through narrower bifurcations) and limit gravity-assisted 
sedimentation (Hinds 1999). For crystalline particles of typical density       
(ca. 1 g.cm-3), a particle size of 5 µm or less is generally agreed to be 
sufficient to penetrate the smallest airways (Prichard 2001, Ganderton and 
Kassem 1992). For simplicity we can classify such particles as having a 
respirable size range.   
 
The method of producing respirable particles for inhalation varies greatly, and 
is dependent upon a number of factors including delivery device and active 
agent. However, the delivery of pharmaceutical products via inhalation can 
usually be classified into three main delivery systems; the nebuliser, the 
pressurised metered dose inhaler (pMDI) and the dry powder inhaler (DPI).   
Both the nebuliser and pMDI aerosolise a solution or suspension of the 
required formulation.  In the case of the nebuliser a constant flow of 
aerosolised droplets is supplied over a required time (either by fine jet, 
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centrifugation or vibration). The nebulised aerosol is generally passed into a 
facemask and delivered to the lung by natural tidal breathing. In comparison, 
pMDI formulations are contained within a pressurised liquid propellant 
(commonly chloro-fluorocarbons (CFC) or hydro-fluorocarbons (HFA)). In 
simple terms, the pMDI device aerosolises a metered quantity of drug 
through a rapid vaporisation process. Patients are taught to co-ordinate the 
depression of the metering valve with their inhalation to insure efficient 
delivery. 
 
Dry powder inhalers harness the energy supplied by the patient's inhalation 
to aerosolise the drug as a powder. Single dose and metered dose devices 
are available with the formulation stored in capsule, reservoir or blister pack 
form. However, all devices work on the same principle by generating a 
turbulent airflow (via propeller, decreasing air channels etc.) to disperse the 
powder formulation. 
 
The dry powder inhaler has many advantages over the pMDI and nebuliser.  
High doses are possible (pMDI is limited to 1mg) and device design may be 
less cumbersome. In addition, co-ordination problems are not encountered, 
as patient inhalation is the driving force for particle aerosolisation. 
Furthermore with the advent of the Montreal protocol, banning the use of 
CFC propellants, in combination with recent concerns over environmental 
issues with HFA propellants, a strong move to dry powder formulation has 
been observed.  
 
The production, handling and aerosolisation of dry powder particles (of 
respirable size), come with a series of unique formulation problems. For 
example, particulates need to be of a suitable size range. Techniques for 
producing such particles include the use of spray drying (Broadhead et al 
1992), supercritical fluids (Shekunov and York 2000) and electrodynamic 




However, the most common route for manufacture of micron-sized 
particulates (<5 µm) is by reducing the particle size of the ‘mother’ crystal 
material. This is achieved by comminution or high-energy milling techniques 
(Staniforth 2000). The subsequent particulates can be classified as having a 
respirable particle size, and the technique of size reduction referred to as 
micronisation. 
 
A consequence of producing particles with a respirable size range is the 
substantial increase in potential adhesive nature. Micronised powders will 
have a high surface-area to mass ratio, since the volume and surface area of 
a sphere are related to the cube and square of the radius. Consequently, the 
force imparted to overcome small particle adhesion will tend to be small with 
respect to the actual adhesion force (Hinds 1999). Thus, the adhesive and 
cohesive forces present in a dry powder inhalation formulation will play a 
dominant role on the storage, handling and eventual aerosolisation efficiency. 
Subsequently, it has become the focus of many DPI investigations and can 
be found in abundance in the literature (Booth and Newton 1987, Kulvanich 
and Stewart 1988, Lord 1993, Safatov et al 1998, Podczeck et al 1997(a, b), 
Podczeck 1998(a), Clarke et al 2002). 
 
Fundamental measurement of such forces would be of great advantage 
when undertaking a formulation program, and have subsequently become 
the focus of this investigation. A brief overview of such particle interaction 




1.2 ADHESION AND COHESION MECHANISMS IN DRY POWDER 
INHALERS. 
 
The development of a dry powder formulation requires knowledge of the 
forces interacting between the individual components in the system.  
Interactions between active drug, carrier, ternary agents and device materials 
will therefore have a net contribution on device performance and efficiency. 
Current strategies for device formulation include, agglomeration (Ikegami et 
al 2000), blending with large and/or fine inert carrier material (ordered mixing) 
(Hersey 1975) and the use of low surface energy materials (Staniforth 1997). 
These systems are not only subjected to inter-particulate forces but also rely 
on them for their operation.  
  
Generally, there are three major attractive forces involved during the 
interaction of particulates in a dry powder system. These are categorised as 
van der Waals, electrostatic and capillary forces. The contribution of each 
force to the total inter-particulate interaction will depend on both the 
environmental conditions and material properties. For example, the 
roughness of two contiguous materials will directly influence the adhesion 
due to factors such as: variation in contact area and degree of vapour 
condensation. On a chemical level each material will have its own intrinsic 
interactive properties based on the molecular structure of the material and 
the way it is ordered as a mass (i.e. crystal structure). Similarly, the affinity of 
a material towards water will directly influence the degree of sorbed water, 
and thus capillary forces. In summary, the forces between one material and 
another will therefore related to the combination of these properties.  
 
A summary of van der Waals, electrostatic and capillary forces (and the 
influence of environmental and physical parameters on them), is given in 
Chapter 1.2.1, 1.2.2 and 1.2.3, respectively. 
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1.2.1 van der Waals Forces. 
 
van der Waals forces represent long-range interactions between atoms.  
These forces can be further categorised as Debye-Induction force, Keesom-
orientation forces and dispersion forces.  
 
Debye-induction forces occur when one molecule containing a dipole induces 
an electrical dipole in a neighbouring apolar molecule resulting in an 
attractive force. Keesom-orientation forces occur when two molecules with 
dipole moments orientate themselves so that the positive pole of one will be 
in contact with the negative pole of the other. 
 
However, the most ubiquitous of the van der Waals forces will be dispersive 
or London forces. Dispersive forces are finite between all atoms and 
therefore all particulate systems.  At any instantaneous moment in time, the 
position of electrons with relation to their nuclear protons will induce a dipole.  
This in turn will induce a polar response in neighbouring atoms resulting in a 
finite attractive mechanism between all atoms (Visser 1989). Haymaker 
developed this theory to calculate the van der Waals forces acting between 
two large semi-infinite bodies by assuming additive molecular forces 
throughout the material (Visser 1989).  However, this was further developed 
by Lifshitz when he eliminated the total additive molecular force in favour of a 
screening affect caused by the atoms present on the surface of the two 
contiguous bodies (Visser 1989, Langbein 1969).  
 
The van der Waals theory can thus be applied to homogeneous macroscopic 
systems with forces acting over a separation distance of 1-100nm (Zimmon 
1982, Podczeck 1998b). The force of interaction between a sphere and a 









=   Equation 1.1.1  van der Waals force of attraction. 
 
Where d is the distance between a perfect sphere and planar surface, r the 
sphere radius and h% the Lifshitz coefficient (an extension of the Haymaker 
coefficient relating the molecular properties to individual materials).  
 
Since the van der Waals forces act over short distances and the subsequent 
adhesion is related to instantaneous dipole poison of the local molecules, it 
stands to reason that, they will be dominated by the contact geometry of the 
contiguous surfaces. For example, the presence of nano-scale asperities on 
the surface of two contiguous bodies would only serve to decrease the van 
der Waals forces acting between them (Biggs and Spinks 1998, Hinds 1999). 
 
1.2.2 Electrostatic Interactions. 
 
Electrostatic forces in dry powder particulate systems can be attributed to 
contact electrification.  Upon contact, electrons will flow from one material to 
the other in order to equal the workfunction of each. Particle separation will 
result in an equal and opposite charge (or contact potential) on the two 
materials; this gives rise to the electrostatic component observed dry powder 
systems (Peart et al 1995, Byron et al 1997). Since pharmaceutical powders 
are mostly insulating organic crystals the electrical relaxation of the material 
(particle resistivity) can be minutes to hours, potentially causing 
unpredictable processing and aerosolisation behaviour. 
 
The electrostatic force (Felec) acting between a charged spherical particle and 








=   Equation 1.2.2 Electrostatic force calculation. 
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Where q is the charge, $o is the permitivity constant and d is the distance 
between the two surfaces. Again such theoretical calculations assume 
perfectly spherical and planar surfaces.  However, in almost all 
circumstances pharmaceutical powders do not conform to such assumptions, 
and thus can result in experimental force values of up to 50 times greater 
than theoretical (Eklund 1995).  
 
The process of contact electrification is generally attributed to both quantum 
mechanics and the surface chemical properties of a material. On a quantum 
level close proximity of atoms in a solid structure causes the individual 
electron levels present in each atom to become less defined energy bands in 
the macroscopic structure.  For a metal, the outer electrons are present in 
valance bands with excitation energy levels being classified as conduction 
bands. The highest filled energy band is labelled the Fermi band with the 
energy required to remove one electron from the surface to infinity being the 
workfunction. 
 
For an insulating material, a region known as a ‘forbidden energy band’ 
separates the valance and conduction bands almost eliminating the 
possibility of electron transition. The transfer of charge between insulators is 
therefore not as well understood as for metals. Charge transfer between such 
materials is likely to take place due to a multitude of material factors. Crystal 
impurities and localised dislocations across a lattice will broaden energy 
bands further; this enables the possible transfer of electrons between 
localised energy bands resulting in a electrostatic behaviour. Gady et al 
(1998) have shown that contact electrification between a polystyrene sphere 
and different conducting materials is only favourable if the difference between 
the electron acceptor sites of the polystyrene overlaps the Fermi level of the 
conductor.  Subsequently, such factors could have a direct impact on DPI 
formulation, for example where the choice of mixing vessel material 




Permanent immobile electrostatic charge due to molecular characteristics 
can also exist in insulating materials due to chemical states and/or 
contamination present on the surface (Bailey 1984). The presence of polar 
groups (electron donors or acceptors) on a surface may result in a 
permanent electrostatic characteristic. Furthermore, ionised surfaces can be 
present on a crystal face even thought the overall charge is neutral.  For 
example the (III) face of sodium chloride can have a positive or negative 
charge dependent on the last layer of ions forming the crystal surface (Führer 
1996).  Finally, stochiometric excess during production can also lead to 
surfaces containing residual ion tensids (Führer 1996). 
 
By applying a workfunction to insulators it is possible to construct an 
electrostatic series. However, it must be stressed that unlike a metal, the 
most energetic electrons will not have a single value; therefore making such 
a series qualitative at best. During mixing or aerosolisation, frequent 
collisions between individual particles will result in interfacial charge transfer 
over the surface. Eliminating frictional forces, this charging will continue until 
a saturation point is reached (Figure 1.2.1) (Bailey 1984).  
 
Figure 1.2.1  Relationship between interfacial charging and charge 
saturation. 
 



























When considering the electrostatic behaviour observed in a bulk powder 
system, interactions other than the simple contact model should be 
considered.  Particle friction due to slip or roll may affect the charging profile 
of two materials (Bailey 1984).  Electrostatic behaviour observed in powder 
handling has therefore been generalised under the title ‘triboelectrification’. 
Triboelectrification during powder handling will be influenced by atmospheric, 
mechanical and physical characteristics.  
 
For example, it has been observed that as the dielectric constant and/or the 
particle size increases, the minimum work required to remove an electron 
from a particle surface to infinity decreases. This makes the transfer of 
charge from large to smaller particles more favourable (Bailey 1984). Such 
observations may also be linked to bipolar charging of pharmaceutical 
powders as reported by Byron et al (1997). 
 
Depending on the resistivity of a material the charge can become 
redistributed over the surface of a particulate. Amorphous spherical particles 
will tend to redistribute charge evenly across the surface, while crystalline 
material will localise the charge at corners or asperities (Führer 1996) thus 
forming iso-energetic regions on a surface (Hersey 1975, Staniforth 1996). 
Where water is present on a particulate surface the redistribution will become 
easier (Führer 1996). It is therefore logical to conclude that at higher 
humidity, electrostatic forces will be less dominant. 
 
Previously, it has been suggested that a specific humidity will exist for charge 
dissipation. At this critical humidity, triboelectrification can no longer take 
place due to the lack of resistivity in the medium (Kulvanich and Stewart 
1988). Furthermore, it has been reported that at higher humidities (~50 to 
80% RH) capillary forces can be considered to dominant particle interactions 
(Kulvanich  and Stewart 1988). However, it is important to note that such 
assumptions will be material specific.  
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1.2.3 Capillary Forces. 
 
Capillary forces exist due to the condensation of water vapour on the surface 
of two contiguous bodies. At a critical point liquid bridges will be formed 
between them, which will become stable when the vapour pressure of the 
liquid bridge equals the partial pressure of the water vapour in the 
surrounding atmosphere (Schubert 1984). The extent of capillary forces can 
be directly related to relative humidity, gap geometry (between the two 
substrates) and the material properties. The chemical affinity of a material for 
water will greatly affect this interaction (Kontny 1988), with capillary forces 
more likely to occur between hydrophilic systems. 
 
Such capillary forces will be substantially reduced in the case of auto-
adhesion, as the meniscus radius will not reach the full particle radius 
(Podczeck 1998b). However, as powders used in inhalation therapy are not 
perfectly spherical or planar systems, the presence of surface asperities, 
surface pores and particle size will affect the contact geometry and thus 
capillary force contribution. Depending on the physico-mechanical and 
chemical properties of the interacting substrates, capillary forces have been 
reported to become apparent at relative humidities of 50% and dominant 
between 65 and 75% (Zimmon 1982). However, it has been shown that 
humidity can have little influence on the adhesion of some materials 
(Kulvanich  and Stewart 1988). 
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1.3 HISTORICAL METHODS USED TO DETERMINE PARTICLE-
PARTICLE INTERACTIONS. 
 
The direct measurement of inter-particulate and particulate-substrate 
adhesion forces enables the collection of data that can be directly applicable 
to powder handling, stability and aerosolisation efficiency in a DPI 
formulation.  
 
Historically, many techniques have been developed to enable the 
measurement of detachment forces for a range of particle sizes. These 
include, centrifugal detachment, aerodynamic methods and ultrasonics. The 
most relative of these techniques are described in more detail here. 
 
1.3.1 Centrifugal Particle Detachment (CPD). 
 
The use of an ultracentrifuge to measure the separation force of powdered 
particulates to various substrates dates back to 1962 (Böhme et al), and has 
been easily adapted for the measurement of pharmaceutical powders.  
Assuming that the substrate and particle are at 90° to the angular velocity, 
the force of separation (Fsep) can be calculated from Equation 1.3.1 
  
Fsep = m#
2rcent Equation 1.3.1  Force for separation (Fsep) by centrifuge 
 
Where m is the particle mass, ! is the angular velocity (rad.s-1) and r the 
radius from the particle to the rotation axis. In addition, deviation from a 90° 
angular velocity allows measurement of both frictional and adhesion forces.  
 
Examples of the centrifugal detachment technique include studies into 
substrate variation (Booth and Newton 1987, Clarke et al 2002), carrier 
based formulation (Staniforth 1980, Lord 1993, Kulvanich and Stewart 1988, 
Podczeck 1998) and the influence of humidity (Podczeck et al 1996, 
Podczeck et al 1997a,b) on the adhesion properties of pharmaceutical 
powder systems.    
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1.3.2 Aerodynamic Particle Re-entrainment. 
 
In simple terms, it is possible to assess the adhesion forces acting on 
particles by removal in a controlled airstream. Such aerodynamic 
determination of adhesion force can be classed under the term re-
entrainment. The re-entrainment of a powder particulate into an airstream is 
dependent on both the adhesion and frictional forces between the powder 
and substrate.  This is due to the airstream being at an angle other than 90° 
below the plane of the surface.  Re-entrainment takes place parallel to or 
above the substrate. Therefore, the force can be related to the detachment 
angle and coefficient of friction.  A commonly used method for aerodynamic 
adhesion studies of pharmaceutical powders is the re-entrainment tube. The 
re-entrainment tube is essentially a long duct containing a sample platform 
mounted down stream from the airflow. Particulate samples are mounted on 
the platform and their removal is assessed as a function of flow rate, 
pressure drop or turbulence through the duct.  
 
Using the re-entrainment tube, Corn and Stein (1965) reported increased 
detachment velocities were required as the particle size and/or surface 
roughness decreased. Further work by Akiyama and Tanijiri (1989) showed 
increased adhesion with increased relative humidity, while Lord (1993) and 
Staniforth (1995) demonstrated how the re-entrainment tube could be applied 
in the measurement of pharmaceutical powders, (showing that an increased 
flow rate and pressure drop is required to entrain finer particulates). Although 
re-entrainment studies do not directly measure adhesion energies, Akiyama 
and Tanijiri (1989) and Lord (1993) have demonstrated good correlation with 
in-vitro and bulk powder analysis techniques. 
 
1.3.3 Miscellaneous Measurement of Detachment Force. 
 
In addition to the two most commonly used approaches (centrifuge and re-
entrainment) a series of other approaches has been employed to measure 
detachment forces between particulates and substrates. These include 
gravimetric, vibrational and impact methods. Zimmon (1982) and Podczeck 
14 
(1998b) give comprehensive reviews of available methods; a brief overview 
of only the most widely used is given here. 
 
1.3.3(a) Separation due to gravity. 
 
The separation force is determined at the point a particulate detaches from a 
surface due to its own mass under gravity. This is generally achieved by 
mounting the sample on a pendulum and increasing its angle consecutively 
until the powder is removed (Zimmon 1982). As most pharmaceutical 
powders are less than 100 µm, gravitational forces are not strong enough to 
overcome the van der Waals forces. Consequently this technique is of little 
use. 
 
1.3.3(b) Separation by impaction. 
 
A hammer is impacted on a fixed substrate back at a known velocity. The 
particulates separate from the substrate, as a function of their mass in 
relation to the conservation of momentum. Again the limiting factor of this 
method is the force required to remove fine particulates. A realistic limit of 
5µm can be removed using the impact technique and therefore is not 
particularly appropriate for measurements on powders designed for 
inhalation. 
 
1.3.3(c)  Separation by vibration.  
 
The separation force is measured as a function of the vibrational energy 
applied to the surface the particles are adhered to. By using ultrasonic 
vibrators with MHz frequencies it is possible to remove micron-sized 
particles. However, there is a high possibility of sample damage due to the 
high frequencies utilised. Subsequently, this method is not generally adopted.  
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1.4 FUNDAMENTAL CONSIDERATIONS AND LIMITATION OF 
HISTORICAL FORCE MEASUREMENT TECHNIQUES. 
 
Although potentially useful, the direct measurement of particle interactions 
using the techniques described in Chapter 1.3 produce data of limited use, as 
they are bulk powder techniques.  Furthermore, fundamental restrictions 
apply, related to the maximum forces that can be imparted on particles of 
respirable size.  
 
For simplicity, such restrictions can be explained by calculating the 
theoretical force required to remove a ‘perfect’ sphere (of given diameter), 
from a planar surface, when subjected to acceleration forces imparted from 
each technique. An empirical formula  (Equation 1.4.1), describing the 
adhesion (Fadh) of a solid sphere to a planar surface, was chosen to 
represent the force of adhesion (Corn 1961, Hinds 1999), while Equation 
1.3.1 was used for CPD calculation. In addition, the equation F = ma was 
used to estimate both the gravitational and re-entrainment forces. 
 
Fadh = 0.063 2r[1+0.009(%RH)]  Equation 1.4.1 Empirical adhesion force 
 
Where d is the particle diameter. By plotting the forces (required to remove 
particles along with the various forces acting on the particles) against particle 
size, the minimum particle size that can be removed using a particular 
technique can be assessed (Figure 1.4.1). 
 
Using the empirical formula for adhesion (Equation 1.4.1), the gravitation 
forces alone would not be effective for removal of particles below 
approximately 0.002 m in diameter. Likewise, under linear acceleration of 
133 m.s-1 (excluding frictional and turbulence considerations) this critical 
diameter would only reduce to around 1mm. Clearly, such forces would not 
be suitable for the measurement of respirable sized material. As expected, 
the centrifugal forces acting on respirable sized particles would be far greater 
than the both gravity and re-entrainment methods. However, using optimum 
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centrifuge settings of 40,000 rev.min-1 at a radius 0.0674 m, (as described by 
Clarke et al 2002) the minimum theoretical particle size detached would be 
around 10 µm.  
 
Essentially, such theoretical calculations (Figure 1.4.1) highlight the 
limitations of current force measurement methodology.   
 
Figure 1.4.1 Theoretical Force required to removal a hydrophobic sphere (of 
specific diameters) from a planar surface plotted alongside theoretical forces 
acting on it due to gravity, and linear accelerations. 
 
However, It is important to note, that such calculations are based on both 
empirical and theoretical equations which assume uniform hydrophobic 
spheres with standardised density (1000 Kg.m-3) at 45% RH. In comparison, 
micronised particles, will to some extent, have irregular surface morphology, 
and will be far from perfect spheres. Subsequently, the forces acting on the 
particles may vary greatly from the theoretical and empirical calculations, due 
to variations in contact geometry. To further satisfy the null-hypothesis that 
particles could be removed using CPD or re-entrainment a preliminary 
investigation was undertaken to examine the detachment force of micronised 
particles from planar surfaces.  
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A detailed overview of the CPD and re-entrainment studies is given in 
Appendix A 1.1 and A 1.2, respectively. Micronised salbutamol sulphate 
(albuterol sulphate) was used as the model particulates and aluminium or 
glass stubs chosen as the adhering substrate. Briefly the CPD followed the 
methodology described by Clarke et al (2002) while a custom-built 
experimental set-up was used for re-entrainment investigation. 
 
Essentially, both techniques indicated individual particles to remain on the 
substrate surface using both maximum centrifugal acceleration and re-
entrainment flow rates (133 m.s-1). Such observations were confirmed 
visually and are shown in Figure 1.4.2 and 1.4.3 for CPD and re-entrainment 
studies, respectively.  
 
 
Figure 1.4.2 CPD particle distributions on aluminium stubs, post 







Figure 1.4.3 Entrainment tube particle depositions (a) prior to and (b) post 
acceleration velocities of 133 m.s-1. 
 
Although previous studies using CDP and re-entrainment have suggested the 
removal of micronised particles possible (using current methodology), the 
most likely explanation for such results would be due to detachment of 
agglomerated material.  
 
Simply put, the majority of micronised particles, when handled, will almost 
certainly form loose agglomerates due to large contact areas and consequent 
cohesive forces. Subsequently, the removal of agglomerated particles, 
deposited on planar surfaces, would be more likely than their individual 






experimental errors would ultimately lead to underestimation of micronised 
particle force values by many orders of magnitude. This can be seen, for 
instance, when considering the CPD or re-entrainment studies; where 
although large percentages of drug particles were removed (agglomerates) 
the individual particles remained.  
 
Although the likelyhood of individual particle detachment does become 
unlikely at the respirable size range, it is important to remember that particle 
substrate adhesion will also be dependent on the physico-mechanical 
properties of the two contiguous surfaces. For example, when using a low 
surface energy substrate (such as PTFE) or material with a nano-scale 
roughness, the adhesion will be significantly decreased, thus increasing the 
potential for removal (Packham 1996, Podczeck 1998b).  
 
However, in most situations this will not be the case. In general, many 
materials used in a DPI will not readily facilitate particle removal. Hence, the 
primary forces influencing aerosolisation efficiency within DPI systems will be 
cohesion forces between the agglomerated micronised particles. 
Subsequently, the measurement of inter-particulate cohesion would provide a 
means of assessing the aerosolisation efficiency of drug particles entrained 
in airstreams during patient delivery.  
 
The potential for using the aforementioned methods to determine such 
interactions would be limited, as it would not allow differentiation between 
agglomerate and particle-particle interactions. Furthermore, both chemical or 
optical determination of detachment forces would produce potential 
problems, as the substrate would be constructed from the same material as 
the particles under observation. The atomic force microscope (AFM) may 
provide a means of overcoming such limitations. 
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1.5 POTENTIAL OF ATOMIC FORCE MICROSCOPY IN DETERMINING 
INTERPARTICULATE INTERACTIONS. 
 
The atomic force microscope (AFM) was developed in 1986 by Binnig et al 
and to date presents itself as the only means of determining the force of 
interaction between a particulate upon approach and retraction from a 
substrate. Force measurements of this type are achieved by attaching a 
sample particulate to a micro-fabricated cantilever probe.  Measurements of 
the forces are determined as a function of the cantilever deflection with 
respect to cantilever/substrate separation. Furthermore, the technique allows 
real time in-situ investigation with little or no sample preparation, without the 
need for chemical or visual analysis. 
 
Although the AFM was proposed as a tool for such colloidal measurements in 
1991 (Ducker et al), literature relating the AFM to pharmaceutical powder 
adhesion is very limited. Indeed, the majority of such reports have been 
published during the course of this investigation (Ibrahim et al 2000, Sindel 
and Zimmermann 2001, Louey et al 2001, Eve et al 2002 ,Berard et al 2002). 
A more comprehensive review of the AFM apparatus is given in Chapter 4. 
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1.6 AIMS OF THE STUDY 
 
The process of micronisation results in the formation of particulates with a 
high surface area and therefore high surface free energy. Subsequently this 
may lead to an unstable cohesive system that would readily agglomerate or 
adhere to surfaces (in order to lower the net free energy). It is believed that 
the cohesive and adhesive forces differ between particulate systems, thus 
leading to large variations in mixing, stability and DPI performance. It is 
proposed that such variations are due to a combination of particulate 
morphology and intrinsic surface energy, with the interactions between these 
systems being dependent upon the environmental conditions in which they 
are processed, stored and delivered. 
 
The primary aim of the study was to characterise the physico-mechanical 
properties of three micronised powders, believed to have significantly 
different surface free energies and physical properties. Three micronised 
drugs, of comparable particle sizes, were chosen for investigation; 
salbutamol sulphate, whose formulation is generally regarded as relatively 
straightforward, disodium cromoglycate (DSCG), a hygroscopic powder, and 
triamcinolone acetonide (TAA), a material recognised for its electrostatic 
charging during handling and processing.  
 
Of particular interest, was the influence of humidity on the interactive 
properties of the three materials, as such environmental factors would 
potentially have different influences on particle-particle cohesion. In order to 
obtain such goals, the materials were first characterised using a series of 
general micromeritic, thermal and imaging techniques. Furthermore, the 
influence of humidity on the water sorption, surface energy and crystal 
structure were analysed under controlled environmental conditions. 
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The primary technique used for particle characterisation was atomic force 
microscopy. A micromanipulation technique was developed to enable the 
attachment of 5 µm particles to AFM cantilevers, while a custom-built 
perfusion apparatus was constructed to allow environmental control. 
Separation energy measurements between individual micronised particles 
and model drug substrates could then be conducted at a range of humidities 
and analysed to produce specific cohesion profiles for each micronised drug. 
 
Finally, for correlation purposes, a series of in-vitro aerosolisation 
investigations for each micronised drug were conducted while contained 
within an environmental humidity test chamber.
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2 GENERAL MATERIALS, METHODS AND CHARACTERISATION. 
 
In order to understand the complexity of such particle-particle interactions the 
micronised drugs were first characterised in terms of particle size, surface 





Micronised salbutamol sulphate (batch no. 300317), micronised 
triamcinolone acetonide (TAA) (batch no. 85BPR) and disodium 
cromoglycate (DSCG) (batch no. F60267) were supplied by Aventis Pharma 
(Holmes Chapel, Cheshire, UK). All solvents used throughout the study were 
supplied by BDH (Poole, Dorset, UK) and were of at least analytical grade. 
Dry nitrogen and helium was supplied by BOC gases (Guilford, UK). Water 
was prepared by reverse osmosis (MiiliQ, Molsheim, France).  
 
The chemical structures for salbutamol sulphate, TAA and DSCG are shown 
in Figure 2.1.1 (a, b and c, respectively) In general, both the chemical and 
macroscopic crystal structure for salbutamol sulphate and TAA are straight 
forward. Salbutamol sulphate contains two salbutamol groups to each 
sulphate group and thus forms a relatively neutral monoclinic crystal system. 
  












































Likewise the structure for TAA is generally considered relatively normal and 
can be compared to other commonly used steroids such as beclometasone 
dipropionate and budesonide (Florey 1972). However, it is important to note, 
little can be found in the literature regarding the crystal structure of TAA. 
 
In comparison, DSCG can be classed as a nematic, chromonic liquid crystal 
that below 93% RH forms a solid solution (Hartshorne and Woodard 1973, 
Cox et al 1971, Chen et al 1999) In simple terms, the crystal structure can be 
considered as a interstitial solid of ‘stacked’ cromoglycate groups (molecular 
rods) held together by water molecules (Hartshorne and Woodard 1973, Cox 
et al 1971) Effectively, disodium cromoglyate will adsorb water into the 
crystal structure and reach a dynamic equilibrium at any specific humidity 
(Hartshorne and Woodard 1973, Cox et al 1971). The adsorption of water 
into the crystal lattice is accompanied by a modification of the cromoglycate 
molecular torsional angles. Such modification will consequently cause minor 
alterations to the crystal structure (Chen et al 1999). 
 
2.2 PARTICLE SIZE. 
 
The particle size distribution of the three micronised drugs was determined 
by laser light scattering. In simple terms, such measurements are achieved 
by measuring the intensity and pattern of scattered light from a laser passing 
through a particulate sample (BSI 1999). In addition, the application of Mie 
theory, taking into account the optical properties of the material, allows 
measurement of particles with a diameter of less than 10µm. Particle size 
distributions are calculated by matching experimental and theoretical 









2.2.1 Materials and Methods. 
 
Particle size analysis was determined by laser light scattering (Mastersizer 
2000, Malvern Instruments, Worcs, UK) using a large volume circulating 
sample dispersion cell.  Approximately 100 mg of powder was suspended in 
a 0.1% w/w lecithin cyclohexane solution and ultrasonicated for 5 minutes at 
25°C prior to analysis (experimentally determined to be sufficient to fully de-
agglomerate each powder (Appendix 2.1)). Cumulative undersize particle 
diameters were calculated and corrected for refractive index using best-fit 
algorithm software. All samples were prepared and analysed in triplicate. 
 
2.2.2 Results and Discussion. 
 
The median particle diameter (d0.5), 10
th percentile and 90th percentile 
undersize values for the three micronised drugs were calculated from the 
particle size distribution and are summarised in Table 2.2.1. In addition, 
graphical representation of the size distributions is detailed in Appendix 2.2. 
 
Drug d0.1 (µm) d0.5 (µm) d0.9 (µm) 
Salbutamol sulphate 0.60 4.79 10.53 
TAA 2.57 4.39 7.48 
DSCG 2.71 5.44 11.12 
 
Table 2.2.1. Particle diameter distributions for the micronised drugs. 
 
Median d0.5 particle diameters for salbutamol sulphate, TAA and DSCG were 
calculated as 4.79 µm, 4.39 µm and 5.44 µm, respectively, using refractive 
indices of 1.29, 1.32 and 1.30, suggesting all three micronised drugs were of 
similar size and were suitable for inhalation applications (Pritchard 2001). In 
addition, the presence of two discrete peaks for salbutamol sulphate 
(between approximately 0.1 and 1 µm and 1 and 11 µm) suggested a 
bimodal particle size distribution with the majority of particles between 1 and 
11 µm. 
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2.3 SURFACE AREA. 
 
Specific surface areas of the three micronised drugs were determined by 
nitrogen adsorption. Briefly, the principle involves measuring the difference in 
pressure between a sample and reference blank, under isothermal 
conditions, after addition of finite quantities of adsorption gas. By applying the 
B.E.T equation, describing monolayer-multilayer surface adsorption it is 
possible to calculate the point of monolayer coverage and thus surface area 















   Equation 2.3.1 BET equation. 
 
Where P is the partial pressure of adsorbate, Va is the volume of gas 
adsorbed at the specific pressure, Vm is the volume of adsorbed gas in a 
monolayer, Po is the saturation point of the adsorbate and C is the BET 










monolayer coverage can be calculated from the slope and intercept. 
 
2.3.1 Materials and Methods. 
 
Specific surface area was measured by 5-point BET nitrogen adsorption 
(Gemini 2360, Micromeritics, Dunstable, UK) at 77 K in triplicate. Samples 
were accurately weighed into standard glass bulbs and dried under nitrogen 
at 40°C for 24 hours prior to analysis (FlowPrep 060 Micromeritics, 
Dunstable, UK). 
 
2.3.2 Results and Discussion. 
 
Specific surface areas for salbutamol sulphate, TAA and DSCG were 




Porosimetry determination works on a similar principle to that of surface area 
calculations (Chapter 2, 2.3). As with surface area determination, in which 
calculations are based on the monolayer-multilayer relationship described by 
the BET theory, condensation of gas in the multilayer region can be 
investigated by incrementing the vapour pressure until saturation (typically 
0.995 P/Po). By calculating the vapour sorption as a function of P/Po, specific 
values for pore diameters can be calculated.  Calculations are based on the 





















    Equation 2.4.1 Kelvin equation. 
 
Where P* is the critical pressure, $ is the liquid surface tension, % is the molar 
volume of condensed vapour, & is the contact angle between the solid and 
condensed phase and rm is the radius of curvature of the meniscus. 
 
In simple terms, the BJH theory assumes a stepwise sorption/desorption of 
adsorbate into surface pores in relation to pore saturation (set arbitrarily at 
around 0.995 P/Po). The relative adsorbate sorption/desorption at each step 
can thus be used to theoretically calculate the volume of pores filled at each 
step. 
 































t  Equation 2.4.2 Adsorbed layer thickness. 
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Thus by combining statistical thickness (t) and Kelvin radius (rK), the pore 
diameter (dp) may be calculated (Equation 2.4.3). 
 
( )kp rtd += *2   Equation 2.4.3  Pore diameter calculation. 
 
2.4.1 Materials and Methods. 
 
Porosimetry of the three micronised drugs were investigated using a 
Micromeritics Tristar 3000 (Micromeritics Dunstable, UK). Samples of each 
micronised drug were dried using the same conditions and experimental 
procedure as described in Chapter 2.3. Approximately 0.5 g of each dried 
sample was weighed into standard sample vials and exposed to a pressure 
cycle of 0.005 to 0.995 (P/P0) at 77 K. 
 
2.4.2 Results and Discussion. 
 
A summary of the relative pore volumes for salbutamol sulphate, TAA and 
DSCG are given in Table 2.4.1 and Figure 2.4.1 
 



















Single point desorption total 
pore volume. 
(<0.8514 nm at P/Po 0.005) 
0.000408 0.000859 0.001309 
BJH adsorption cumulative 
pore volume. 
(1.7-300 nm pore diameter) 
0.008242 0.011106 0.02327 
BJH desorption cumulative 
pore volume. 
(1.7-300 nm pore diameter) 
0.008169 0.01102 0.023246 
 
Table 2.4.1 Pore volumes (<300 nm) for the three micronised drugs. 
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The cumulative pore volumes for all three micronised drugs were relatively 
low. However, this was to be expected, as the materials were essentially 
crystalline and would therefore not contain a large amount of pores. 
 
It would be envisaged, that the majority of ‘pores’ present on the surface 
would be due to a combination of factors, including cracks and crevices 
(induced during the milling process), variation in particle size (i.e. small 
crystallites (<100 nm) throughout the powder) and intrinsic crystal surface 
defects (produced during the crystallisation process). 
 
Figure 2.4.1 Pore volumes (<300 nm) for the three micronised drugs. 
 
The cumulative pore volumes for DSCG were approximately twice that of 
salbutamol sulphate or TAA. Although this may be related to the presence of 
mechanically induced surface damage, one possibility is the influence of 
crystal structure. In simple terms, the crystal structure of DSCG can be 
classified as a series of DSCG molecules stacked to form ‘rods’, which are 
held together by interstitial water molecules in the form of channels. It 
therefore stands to reason, that in a ‘dry’ state, a similarly sized molecule 
such as nitrogen could easily fill the channels. 
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2.5 TRUE DENSITY. 
 
True density measurements were determined by helium pycnometry. 
Measurements are preformed by measuring the pressure change of helium in 
a calibrated volume in relation to a known mass with unknown volume (Webb 
an Orr 1997). 
 
2.5.1 Materials and Methods. 
 
True density measurements were determined using helium pycnometry 
(Accupyc 1330 Gas Pycnometer, Micromeritics, Norcross, GA).  Samples 
were prepared by drying in open pans at 40°C for 24 hours prior to analysis. 
The temperature was maintained at 27°C during out-gassing and analysis. 
Each sample was run ten times. 
 
2.5.2 Results and Discussion. 
 
True density measurements for salbutamol sulphate, TAA and DSCG were 






Accurate solubility values for the three micronised drugs were determined in 
order to understand the affinity and interactions of the drugs with water. 
 
2.6.1 Materials and Methods. 
 
A supersaturated solution of drug in water was prepared by continued 
addition of drug to approximately 20 ml water (reverse osmosis, Millipore, 
Watford, UK). Samples were agitated in a gyratory water bath shaker (G76, 
New Brunswick Scientific, New Jersey, USA) at 25° C for 48 hours prior to 
analysis.  Each sample was filtered (under vacuum) through a 0.4 µm 
cellulose acetate filter. The collected solution was then re-filtered through a 
0.1 µm PTFE single use syringe filter (Whatman, Madison, UK). The 
recovered solution was weighed and dried in an oven at 50°C. The 
recovered, dry mass was reweighed and solubility calculated. Samples were 
analysed in triplicate. 
 
2.6.2 Results and Discussion. 
 
Solubility for the three micronised drugs in water is given in Table 2.6.1. As 
expected, the sulphate of salbutamol was freely soluble in water, while the 
TAA can be classified as practically insoluble. In addition, the solubility for 
DSCG could not be accurately recorded as it formed a lyotropic, chromonic 
liquid crystal. (Cox et al 1971, Hartshorne and Woodard 1973). This 
observation was confirmed by observation of DSCG under a microscope 
using a crossed polarised filter. 
 
Salbutamol sulphate 42.1 ± 0.3% w/w 
TAA 0.0097± 0.0001% w/w 
DSCG N/A* 
 
Table 2.6.1. Solubility values for salbutamol sulphate, TAA and DSCG in 
water at 25°C. N/A* DSCG formed a lyotropic chromonic liquid crystal. 
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2.7 DIFFERENTIAL SCANNING CALORIMETRY. 
 
The influence of heating on the thermal properties of the micronised drugs 
was investigated using differential scanning calorimetery (DSC). In principle, 
DSC operates by measuring the heat flow associated with chemical changes 
in a material (i.e. crystallisation or melting) in relation to change in 
temperature. This is achieved by measuring the current required to maintain 
an equal heat flow to both a sample and reference during heating or cooling 
(Charsley and Warrington 1992). 
 
2.7.1 Materials and Methods. 
 
Thermal properties of the micronised drugs were investigated using a 
differential scanning calorimeter (DSC 2920, TA instruments, Surrey, UK). 
Approximately 5-10 mg of micronised drug was accurately weighed into a 
DSC sample pan and crimped with a lid to form a hermetic seal.  The sample 
and reference (empty hermetically sealed pan) were heated using a 10 
ºC.min-1 ramp rate. Calibration of the DSC was checked by measurement of 
an indium standard (melting point, 156.6°C). 
 
2.7.2 Results and Discussion. 
 
Representative thermograms of salbutamol sulphate, TAA and DSCG are 




Figure 2.7.1 Differential scanning calorimeter thermographs of (a)salbutamol 





The DSC thermograph for salbutamol sulphate (Figure 2.7.1a) suggested an 
isothermal response with respect to heat flow until an endothermic response 
was observed with a peak at approximately 205°C (suggesting a melt with 
decomposition). In general, such observations were in good correlation with 
previously published data (Ward and Schultz 1995). 
 
Analysis of the DSC thermographs for TAA suggested a relatively stable 
isothermal behaviour (with respect to temperature), until a large endothermic-
exothermic response was observed at approximately 294°C. Such 
observations suggested a melting with subsequent degradation (Figure 
2.7.1b), and are in good agreement with previously reported studies (Florey, 
K 1972). 
 
In contrast, the thermal response for DSCG (Figure 2.7.1c) produced a wide 
endothermic response from approximately 100°C to 250°C, indicative of 
water loss and melting of a hydrated organic material (Charsley and 
Warrington 1992). Again, such observations are in good agreement with 
previously published work (Cox et al 1971), which demonstrated DSCG to 
undergo a complex phase transition when heated. 
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2.8 THERMOGRAVAMETRIC ANALYSIS. 
 
The influence of heating on the mass change of the three micronised drugs 
was investigated using thermogravametric analysis. In simple terms the 
technique involves suspending a sample (typically 10-100 mg) from a 
microbalance, inside a cylindrical oven cell. Nitrogen is passed through the 
cell, and the oven is heated by a programmable temperature controller. 
Changes in mass can thus be recorded as a function of temperature and/or 
time. A more detailed description of this technique can be found elsewhere 
(Charsley and Warrington 1992). 
 
2.8.1 Materials and Methods. 
 
Approximately 50 mg of sample was weighed onto a tarred, open sample pan 
in the thermogravametric analyser. (TGA 1 Thermogravametric analyser, 
Perkin Elmer Instruments, Connecticut, USA). Samples were heated from 
25°C to 250°C at a rate of 5°C.min-1. 
 
2.8.2 Results and Discussion. 
 
Representative mass vs. temperature plots for salbutamol sulphate, TAA and 
DSCG are shown in Figures 2.8.1, 2.8.2 and 2.8.3, respectively. Mass vs. 
temperature plots for the three drugs are plotted on equivalent scales for 
comparative purposes. In addition, detailed (smaller scale) temperature axis 
plots for salbutamol sulphate (Figure 2.8.1b) and TAA (Figure 2.8.2b) are 
also included to allow closer examination of mass change. 
 
The relative mass for salbutamol sulphate (represented as a percentage) 
decreased relatively little over the temperature range 25°C~175°C, with a 
~0.1% w/w mass loss most likely being attributed to the removal of surface 
adsorbed moisture. In addition, a large drop in relative mass was observed at 







Figure 2.8.1 Thermogravametric response for Salbutamol sulphate. (25°C - 




The relative mass for TAA decreased by approximately 1.2% w/w over the 
temperature range 25°C to 250°C, with the majority loss between 25°C and 




Figure 2.8.2  Thermogravametric response for TAA (25°C - 250°C at 5°C.s-





Figure 2.8.3  Thermogravametric response for DSCG – 
(25°C - 250°C at 5°C.s-1). 
 
In contrast, the mass loss for DSCG over the temperature range 25°C-250°C 
was far greater (~12%) than salbutamol sulphate and TAA. Such 
observations are expected, however, as DSCG is reported to contain up to 
nine water molecules per molecule of DSCG (Cox et al 1971). In addition, an 
inflection in the mass vs. temperature curve (~100°C) suggests a metastable 
region. Since the DSCG crystal requires water molecules to hold the 
structure together (Chen et al 1999), it stands to reason that a critical, stable 
region would exist, below which an amorphous collapse will occur. 
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2.9 SCANNING ELECTRON MICROSCOPY. 
 
General morphology of the three micronised drugs was investigated by 
scanning electron microscopy (SEM). In simple terms, SEM generates high-
resolution images of conducting samples, by collecting and analysing the 
secondary electrons (weekly bound conduction-band electrons) ejected as a 
result of high-energy electron beam collisions. 
 
2.9.1 Materials and Methods. 
 
Particle morphology of salbutamol sulphate, TAA and DSCG were 
investigated using cryogenic low temperature scanning electron microscopy 
(JEOL 6310, JEOL, Japan) at 10 KeV, using a method described elsewhere 
(Clarke et al 1998)*. 
 
2.9.2 Results and Discussion. 
 
Low temperature scanning electron micrographs for the micronised 
salbutamol sulphate, TAA and DSCG samples are shown in Figure 2.9.1 (a, 
b and c, respectively). Representative photomicrographs of the ‘as supplied’ 
salbutamol sulphate and DSCG (Figure 2.9.1, a and b) suggest that the 
crystals have a columnar crystal shape. Photomicrographs of the ‘as 
supplied’ TAA (Figure 2.9.1c) suggest the crystal form to have an irregular 
plate-like crystal shape. 
In addition, large variations in crystal size were observed for all three drugs. 
This observation correlates well with particle size data (Section 2.1) and can 





                                            
*
 Scanning electron micrographs taken elsewhere in the thesis used conventional SEM and 
not LTSEM. Samples were imaged on a Jeol 6310, (Jeol Japan) at 10 KeV. Samples were 
gold coated prior to analysis (Edwards Sputter Coater, UK). 
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Figure 2.9.1. Low temperature scanning electron micrographs (magnification 
X 15,000) of (a) salbutamol sulphate, (b) DSCG and (c) TAA. 
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2.10 GENERAL DISCUSSION. 
 
From preliminary investigations into the physical properties of the three 
micronised drugs, it becomes clear that large variations in (for example) 
particle size, morphology, thermal response and solubility exist. Such 
differences are to be expected however, as the three materials are 
chemically very different, and will subsequently have very specific physico-
chemical and mechanical properties. 
 
Such large variations in the physico-mechanical nature of the three 
micronised drugs may potentially influence all aspects of formulation, storage 
and delivery to the patient. For example characteristics such as density, 
surface area and morphology will directly influence inter-particulate adhesion 
forces (Hinds 1999). In addition, thermal analysis, solubility and pore size 
calculations indicate that the three materials to have varied degrees of water 
affinity (sorption and/or hydration). Such observations suggest potential 
variations in capillary condensation for the three micronised drugs, which 
would ultimately influence the degree of capillary interaction. 
 
Consequently, a series of investigations were undertaken to determine the 
influence of relative humidity on the physico-mechanical properties of the 
three micronised drugs in an attempt to assess the impact of humidity on dry 
powder aerosolisation performance. 
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3 INFLUENCE OF HUMIDITY ON THE PHYSICAL PROPERTIES OF 




As previously discussed, the presence of adsorbed and/or absorbed water in 
pharmaceutical dry powder systems may directly influence the magnitude of 
the specific forces (i.e. Van der Waals, electrostatic and capillary forces) 
contributing to the total interaction mechanism.  Consequently, a series of 
investigations were undertaken to determine the influence of relative humidity 
on the physico-mechanical properties of salbutamol sulphate, TAA and 
DSCG in an attempt to assess the impact of humidity on potential dry powder 
aerosolisation performance. 
 
3.2 KARL FISCHER WATER DETERMINATION. 
 
Equilibration water content of each of the micronised drugs was determined 
by coulometric Karl Fischer water titration.  In simple terms, the reaction of 
water with iodine and sulphur dioxide in the presence of an alcohol and base 
can be measured as a function of remaining iodine present in solution.  
 
Reaction 1:  !! +"++ RNHSOCHRNOHCHSO
3332
 




In a coulometric Karl Fischer titration, the iodine is electrolytically generated 
from the anolyte and monitored by platinum electrode.  As long as water is 
present in the reaction cell, a proportional current will be generated to 
produce the iodine.  The reaction between one mole of water and iodine is 
equivalent to a charge of 10.72 C.mg-1, therefore allowing total water content 
to be measured as a function of electrical input. A more detailed description 




3.2.1 Materials and Methods. 
 
Equilibration water content of each of the micronised drugs was determined 
by storing small samples (<100 mg) of the micronised materials, in tightly 
sealed containers, together with different saturated salt solutions for 12 hours 
at a series of specific relative humidities (Appendix 3.1).  Each powder was 
then accurately weighed (~100 mg for salbutamol sulphate and ~20 mg for 
TAA and DSCG), and placed directly into the titration cell before being 
analysed for total water content (n=3) by coulometric Karl Fischer Titration 
(MKC-510E, Kyoto Electronics, Tokyo).   
 
3.2.2 Results and Discussion. 
 
Equilibrium moisture content values for salbutamol sulphate, TAA and DSCG 
are given in Appendix 3.2.  Moisture sorption profiles, shown graphically in 
Figure 3.2.1 suggested a significant (ANOVA p<0.05), positive increase in 
water content, for all three micronised drugs, as the storage humidity is 
increased. The water content of salbutamol sulphate was the least affected 
by storage humidity, increasing from 0.11 ± 0.01% w/w at 0% RH to 0.19 ± 
0.03% w/w water content after storage at 84% RH. The TAA water content 
increased from 0.63 ± 0.06% w/w at 0% RH to 1.97 ± 0.03% w/w after 
storage at 84% RH.  In comparison the DSCG water content increased from 
3.17 ± 0.55 at 0% RH to 17.17 ± 0.31% w/w on storage at 84% RH. 
 
In order to compare the significance of these variations a Fisher pairwise 
analysis (p<0.05) was performed on each of the three drugs at paired 
humidities.  Although significantly different across the humidity range 
(ANOVA p<0.05), pairwise analysis indicated the influence of humidity on 
salbutamol sulphate to be significant between 11 and 29% RH only.  
Furthermore, analysis of the unpaired humidities suggested no significant 
variance above 29% RH. Fisher pair wise analysis for both TAA and DSCG 
water content after storage at varied specific humidities suggested all paired 
and unpaired humidities to statistically affect water sorption. 
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Figure 3.2.1  Moisture sorption profiles, obtained by Karl Fischer water 
titration, for ! salbutamol sulphate, ! TAA and " DSCG (n=3). 
 
However, it is important to note that mean water content after storage in a 
humidity free environment was 0.11, 0.63 and 3.17% w/w for salbutamol 
sulphate, TAA and DSCG, respectively.  This observation suggested either 
incomplete de-sorption of water or the possibility of molecularly bound water 
in the crystal structure. However, the most likely explanation is experimental 
error.  Although the utmost care was taken in determining specific water 
content, the kinetics of water sorption after storage at 0% RH would be very 
rapid upon exposure to ambient conditions.  In addition, the lack of statistical 
significance in water content for salbutamol sulphate may possibly be 
attributed to the lack of resolution when attempting to measure such small 
quantities of water. In order to further investigate these phenomena, dynamic 
vapour sorption of the three micronised drugs was undertaken. 
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3.3 DYNAMIC VAPOUR SORPTION. 
 
The Influence of humidity on water sorption and de-sorption for salbutamol 
sulphate, TAA and DSCG was investigated gravimetrically, using dynamic 
vapour sorption (DVS).  Briefly, the DVS, as shown graphically in Figure 
3.3.1, consists of a 7 Figure Cahn microbalance housed inside a 
temperature-controlled cabinet. Relative humidity is controlled by mixing 
ratios of humidified and dry nitrogen together using two independent mass 
flow controllers, before passing over the balance reference and sample cell. 
 
 
Figure 3.3.1 Schematic diagram of a DVS (Modified from DVS SMS 















Sample cell Reference cell
Nitrogen flow
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3.3.1 Materials and Methods. 
 
Moisture sorption profiles for salbutamol sulphate, TAA and DSCG were 
determined by DVS (DVS-1, Surface Measurement Systems Ltd, London, 
UK). Approximately 10mg of sample was weighed into the sample cell and 
subjected to two 0-90% RH cycles, over 10% RH increments. Equilibration 
moisture content at each humidity was determined by a change in mass to 
time ratio of 0.002 dm/dt.  
 
3.3.2 Results and Discussion. 
 
Time vs. equilibrium moisture content for salbutamol sulphate, TAA and 
DSCG are shown graphically in Figures 3.3.2a, 3.3.3a and 3.3.4a, 
respectively. In addition, DVS moisture sorption isotherms, calculated as 
percentage dry mass, for salbutamol sulphate, TAA and DSCG are shown in 
Figures 3.3.2b, 3.3.3b and 3.3.4b, respectively.  
 
The water sorption isotherms for salbutamol sulphate (shown in Figure 
3.3.2b) follow a sigmoidal class L-3 curve (Giles et al 1960) suggesting multi-
layer water sorption onto the crystal surfaces. Monolayer coverage of water 
can be calculated from the slope and intercept of the linear BET single point 
equation from data obtained around the first inflection (Chapter 2). Values 
(R2 = 1) of 0.06% w/w water for monolayer coverage and 2.24 m2.g-1 for 
surface area were determined from the DVS data, using a projected water 
molecule surface area of 11.13 x 10-20 m2 (Webster et al 1998). This 
correlated well with the surface area measurements obtained by nitrogen 
adsorption of 3.76 m2.g-1 with predicted water monolayer coverage of 0.06% 
w/w. 
 
Regression analysis indicated monolayer coverage (0.06% w/w) to occur at 
23% RH, suggesting that separation energy measurements conducted by 





Figure 3.3.2 (a) Moisture sorption profile and (b) corresponding moisture 
sorption isotherms for salbutamol sulphate. 
 
In comparison, analysis of the moisture sorption curves for TAA and DSCG 
suggests non-Langmuir type isotherms and thus would not allow such 







Figure 3.3.3 (a) Moisture sorption profile and (b) corresponding moisture 
sorption isotherms for TAA. 
 
The relative percent moisture sorption for TAA was approximately one order 
of magnitude greater than that of salbutamol sulphate. Since the surface 
areas were of similar order (3.76 and 5.14 m2.g-1 for salbutamol sulphate and 
TAA, respectively) this suggests TAA has a higher affinity for water. Thus, it 
is proposed that the moisture sorption curve for TAA may be a class H curve 
(Giles et al 1960). Class H curves are essentially a ‘high affinity’ form of the L 





Figure 3.3.4 (a) Moisture sorption profile and (b) corresponding moisture 
sorption isotherms for DSCG. 
 
Moisture sorption isotherms for DSCG (Figure 3.3.4b) suggest a class C 
sorption curve (Giles et al 1960). Class C curves are indicative of porous 
materials, with a high affinity for the adsorbate, and suggest absorption into 
the crystal structure. This is to be expected however, as DSCG is essentially 
a solid solution, whose crystal structure contains channels that allow the up 
to nine molecules of water per molecule of DSCG (depending on the relative 
humidity), before collapsing into a series of liquid crystal mesomorphs 




In, addition a plot of the moisture sorption and desorption (two cycles) rate 
kinetics for the three micronised drugs are shown in Figure 3.3.5. Data were 
based upon a nominal 10mg sample and assumed equilibrium moisture 
content at a dm/dt of 0.002. 
 
Figure 3.3.5 Influence of humidity on the rate kinetics of the micronised 
drugs exposed to two humidity ramp cycles (approximately 10mg) 
 
The rate of moisture sorption and desorption for both salbutamol sulphate 
and TAA was relatively rapid with equilibrium being reached in less than 60 
minutes at each humidity step. In comparison, the moisture kinetics for 
DSCG was significantly slower, with equilibrium times of up to 4 hours at 
some steps. This is mostly likely due to the rate at which water can penetrate 
into the crystal structure (Hartshorne and Woodard 1973, Chen et al 1999). 
Essentially, such observations indicate that DSCG should be stored for a 
minimum of four hours when equilibrating at a specific humidity. However, it 
is important to note, the data was not normalised for mass, and larger 
masses will inevitably require longer equilibration times. Subsequently 
storage times of &12 hours were instigated for equilibration storage of all 
micronised powders used in the in-vitro studies (Chapter 5), while a minimum 
of 60 minutes (for salbutamol sulphate and TAA) and 4 hours (for DSCG) 
were chosen for the AFM studies (Chapter 4). 
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3.4 X-RAY POWDER DIFFRACTION. 
 
X-ray powder diffraction works on the same principle to that of conventional 
X-ray crystal analysis. Just as light is diffracted through a grating, a 
monochromatic X-ray will be diffracted by the atomic spacing that exist 
between the atoms in an ordered crystalline material. By rotating the crystal 
in relation to the X-ray beam, the three-dimensional structure can be 
calculated from the diffracted X-rays that pass between the crystal planes. 
For crystalline powder samples, the orientation of the crystalline material will 
be random, and thus the monochromatic X-ray will produce a diffraction cone 
of semi apex angle 2'. Although this does not allow finite structural 
determination, it does provide a unique diffraction pattern that is particular to 
the material under investigation. A detailed account of the theory is given 
elsewhere (Guinier 1994). 
 
3.4.1 Materials and Methods. 
 
X-ray diffraction spectra of salbutamol sulphate, TAA and DSCG at varied 
humidity were obtained using an X-ray powder diffraction system with 
perfusion unit add-on (D5000, Bruker AXS, Cheshire, UK). Settings were as 
follows; Fast scan, 2 to 39.960 2-Theta, step size 0.036 2-Theta, step time 
0.5 seconds Temp 25°C. X-ray powder diffractographs were taken at 15, 45 
and 75% RH (±5% RH). 
 
3.4.2 Results and Discussion. 
 
X-ray powder diffraction patterns of salbutamol sulphate, TAA and DSCG 
presented in Figure 3.4.1, 3.4.2 and 3.4.3, respectively, suggested good 
correlation with diffraction patterns found in the literature (Ward and Schultz 




Figure 3.4.1  X-ray powder diffraction patterns of salbutamol sulphate, 
overlaid at 15, 45 and 75% RH. 
 
Figure 3.4.2  X-ray powder diffraction patterns of TAA, overlaid at 15, 
45 and 75% RH.  
 
Comparison of the XRPD patterns for salbutamol sulphate and TAA (overlaid 
in Figure 3.3.1 and 3.3.2, respectively) exhibited no change in diffraction 
patterns at 15, 45 and 75% RH, suggesting that the presence of water 
vapour had no influence on the crystal lattice. In contrast, the staggered 
diffraction patterns for DSCG taken at 15,30 and 75% RH (Figure 3.3.3), 
exhibited subtle differences in the relative peak intensities. Such 
observations have been reported previously and are most likely related to the 
sorption of water into the crystal lattice (Chen et al 1999). 
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Figure 3.4.3  X-ray powder diffraction patterns of DSCG, staggered at 
15, 45 and 75% RH.  
2-Theta - Scale























3.5 INVERSE GAS CHROMATOGRAPHY. 
 
As previously discussed, the adhesion/cohesion of two contiguous surfaces 
will be dependent on both the dispersive (#s
d) and polar (#s
sp) components of 
the surface free energy (Podczeck 1998b). Techniques, such as contact 
angle (Good 1992) and capillary intrusion (Desai et al 2002) have previously 
been used to determine surface free energy of pharmaceutical materials. 
However, for micronised materials, these techniques tend to be limited, due 
to unpredictable surface morphology (contact angle issues) and mass of 
sample required (capillary intrusion). The use of inverse gas chromatography 
(IGC) may provide a means of determining both dispersive and polar 
components of surface free energy for micronised drugs without such 
limitations (Ticehurst et al 1994).   
 
Inverse gas chromatography is essentially a modification of normal phase 
gas chromatography. In normal phase gas chromatography, columns are 
packed with a known stationary phase, and the analyte separated or 
quantified by the relative retention time from the mobile gas phase. In 
comparison, IGC columns are packed with the analyte (in this case, 
micronised powder) and the retention times of known sample probes are 
measured from the mobile gas phase.  
 
Since apolar liquids (e.g. n-alkanes) will interact by dispersive forces only, it 
stands to reason that a direct relationship between molecular mass and 
retention time will exist. Such a response can be expressed using Equation 








5.05.0 )()(2ln !!      Equation 3.5.1 
 
Where R is the gas constant, T the temperature, N Avogadro’s number, a is 
the projected surface area of the sample probe, #l
d the dispersive component 
of the probe and VN the net volume of carrier gas required to elute the probe 
molecules from the column (corrected for column dead time and compression 
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factors). Hence by plotting RTlnVN against a(#l
d)0.5 for a series of n-alkanes, 
the dispersive component (#s
d) of the analyte can be calculated from the 
slope. 
 
In addition, by using a series of polar probes, the acidic-basic component of 
the analyte can be investigated. By plotting the polar probe retention volume 
(RTlnVN) against a(#l
d)0.5, the specific polar interaction can be calculated by 
measuring the vertical distance between the polar probe and n-alkane linear 
fit line ((Gsp). Furthermore, by a assigning specific donor numbers (DN) and 
corrected acceptor numbers (AN), based on the Lewis acid-base concept 



















  Equation 3.5.2 Acid-base calculation. 
 
Where Ka and KD can be obtained from the slope and intercept.  
 
Furthermore, by passing the carrier gas through a perfusion system, it 
becomes possible to investigate the influence of humidity on the surface 
energetics of a specific powder sample. 
  
3.5.1 Materials and Methods. 
 
The surface free energy components of micronised salbutamol sulphate, TAA 
and DSCG were determined using a commercially available IGC (SMS IGC 
2000, Surface Measurement Systems Ltd, London, UK). A schematic of the 




Figure 3.5.1. Schematic diagram of the IGC apparatus. (modified from SMS 
IGC pharmaceutical application note, Surface Measurement Systems Ltd, 
London, UK). 
 
Powder was weighed into standard glass IGC columns and plugged with 
glass wool. Each column was tapped for five minutes, using the minimum 
setting on a jolting voltumeter (Surface Measurement Systems Ltd, London, 
UK) to a produce 'uniform' powder bed. Each column was equilibrated in the 
IGC at 0% RH, at 318.05 K, under dry nitrogen for 12 hours prior to analysis. 
The retention time of a series of n-alkanes (hexane to decane) and polar 
probes (ethanol, ethyl acetate and acetone) were analysed at infinite dilution 
by flame emission detector. Column settings and run times for all three drugs 
were optimised at 318.05 K. Approximately 0.5 g of salbutamol sulphate and 
TAA were used for each column while 0.25 g of DSCG was used (due to 
increased retention times). For each column, one run was conducted at three 
relative humidities (0% RH then 15% RH then 75% RH), with a six hour 
equilibration time being instigated after humidity was altered. 
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3.5.2 Results and Discussion. 
 
Micronised salbutamol sulphate, TAA and DSCG samples were analysed by 
IGC at 0, 15 and 75% RH using both apolar and polar probes. An example of 
the apolar linear response and polar probe retention times for a salbutamol 
sulphate column at 0% RH is shown in Figure 3.5.2. 
 
Figure 3.5.2 Plot of RTlnVg against a($
d
L)
0.5 for salbutamol sulphate at 0% 
RH. 
 
The specific surface free energy components (calculated from the probe 
retention time) are shown in Table 3.5.1. Corrected donor DN' numbers 
(Gutmann 1978) and acceptor numbers AN' (Riddle and Fowkes 1990), used 
for the estimation of the acidic and basic components of the surface free 
energy, were as follows (AN':DN') Acetone 42.5:8.7, Ethyl acetate 42.8:5.3 
and  ethanol 50:35.9. 
 
Analysis of the IGC data indicated both salbutamol sulphate and TAA had 












Ka acidic Kb (basic) 
Salbutamol - 0 44.6 0.0047 0.0740 
Sulphate 15 38.3 0.0049 0.0739 
 75 40.5 0.0036 0.1420 
TAA 0 47.4 0.0041 0.1620 
 15 46.6 0.0043 0.1786 
 75 49.9 0.0036 0.3095 
DSCG 0 80.7 0.0043 0.4776 
 15 65.5 0.0038 0.3497 
 75 63.7 0.0024 0.3257 
 
Table 3.5.1 Surface energy components) of three micronised drugs at 
controlled humidity. 
 
Relative humidity had little influence on the dispersive component of 
salbutamol sulphate or TAA. In comparison, DSCG had a much higher 
dispersive energy than salbutamol sulphate and TAA. At 0% RH the 
dispersive energy for DSCG (~80 mJ.m-2) was almost double that of 
salbutamol sulphate and TAA. As humidity was increased, the dispersive 
energy decreased to around 60 mJ.m-2. However, this was still around 20 
mJ.m-2 higher than salbutamol sulphate and TAA. One possible explanation 
for such observations may be due to the molecular channels existing through 
the DSCG crystal structure (Hartshorne and Woodard 1973). Essentially, at 
0% RH, DSCG will have a significantly reduced quantity of water molecules 
present in the interstitial crystal structure and thus, have a higher affinity for 
adsorbates.  
 
Analysis of the acidic (Ka) and basic (Kb) polar contributions to the surface 
free energies indicated all three micronised drugs to have similar acidic 
contributions (around 0.004). In comparison the basic component indicated a 
trend salbutamol sulphate < TAA < DSCG. The reason for such variation will 
be both chemical and physical (i.e. functional groups dominating crystal 
planes and the chemical structure of the active molecule), and will be 
discussed later (Chapter 6). 
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3.6 GENERAL DISCUSSION. 
 
Investigation into the influence of humidity on the physical properties of 
salbutamol sulphate, TAA and DSCG has shown each micronised drug to 
have very different moisture sorption profiles, crystal structure and surface 
free energy. 
 
Consequently, it would be envisaged that cohesive interactions between 
each micronised drug may vary with respect to humidity. Since globalisation 
and mass travel could potentially expose commonly used prescription 
medicines (such as the micronised drugs used here) to large variations in 
climate (for example; 0% RH in North Africa to 100% RH in S.E. Asia (Anon. 
2002)), the degree to which humidity influences cohesion could potentially be 
crucial. 
 
To investigate further, the influence of humidity on drug cohesion, the AFM 
colloid drug probe technique was utilised (Chapter 4).  
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The atomic force microscope colloid probe technique was used to 
quantitatively measure the influence of humidity on the cohesive interactions 
of micronised salbutamol sulphate, TAA and DSCG at specific humidities.  
 
The atomic force microscope was developed in 1986 and is commonly used 
for the high-resolution (sub-angstrom) topographical imaging of surfaces 
(Binnig et al 1986). However, the technique was further developed to allow 
the measurement of forces acting between a tip and substrate under specific 
media (Ducker et al 1991) 
   
In simple terms, the AFM consists of a micro-fabricated cantilever whose 
deflection is recorded (usually by laser reflection) as it interacts with a moving 
substrate. Direct measurement of force can be determined by ramping the tip 
vertically (Z axis), towards, and away from a sample. The relative deflection 
of the cantilever as the tip approaches, makes contact with, and is removed 
from a surface produces a force-distance curve. Hysteresis in the approach 
and retraction cycles of the force distance curve can be related to the 
magnitude and type of forces acting between the two surfaces (Heinz and 
Hoh 1999). By applying Hookes law (Equation 4.1.1) relating the extension of 
a spring under applied load, the forces acting between the cantilever tip and 
surface can be calculated.  
  
c
kDF =       Equation 4.1.1 Hookes law. 
 
Where Dc is the cantilever deflection, F the force acting on the cantilever (N) 





A schematic representation of an ideal force-distance curve is shown in 
Figure 4.1.1. Initially, as the tip is brought towards a surface there is no 
interaction and therefore no deflection of the cantilever (Figure 4.1.1a). This 
continues until the short-range van der Waals forces overcome the cantilever 
spring constant and pulls the tip onto the sample surface (Figure 4.1.1b). 
Continued vertical movement of the surface is met by a linear response in 
cantilever deflection (Figure 4.1.1c, d) as a predetermined cantilever load is 
applied and removed. This area is referred to as the region of constant 
compliance; lack of linearity within this region indicates tip and/or surface 
deformation.  
 
Continued retraction from the surface results in an extended cantilever 
deflection related to the adhesion properties between the cantilever tip and 
surface (Figure 4.1.1e). The cantilever deflection due to the tip adhesion is 
overcome when the cantilever spring constant is greater than the adhesion 
forces between the two surfaces. The maximum deflection value relative to 
point of no deflection is equal to the adhesion force. Continued removal from 
the surface to the initial height above the surface produces no deflection 
(Figure 4.1.1f). Integration of the area within the adhesion portion of a force-
piezo distance curve will be equal to the energy of separation. The main 
advantage of determining separation energy (esep) is that it takes into account 
variations in mechanical properties between the tip and substrate, thus 






Figure 4.1.1  Schematic representation of an ideal force curve 
between an AFM cantilever drug probe and substrate, (a.) approach of probe 
with no cantilever deflection, (b.) jump to contact, (c) point of no applied 
force, (d) applied cantilever deflection equals applied deflection, (e) negative 
deflection due to probe adhesion, (f) retraction of probe with no cantilever 
deflection. 
 
As previously discussed, the AFM force measurement approach can be 
further modified by incorporating a colloidal material onto the cantilever tip, 
allowing direct measurement of interactive forces between a particulate and 
substrate.  
  
Previous investigations using cantilever mounted colloidal probes have 
mainly focused on the physical interactions between inorganic polymeric 
spheres and atomically flat substrates (Biggs and Spinks 1998, Yalamanchilli 
et al 1998). However, the technique has rapidly diversified into areas such as 
biotechnology (Heinz and Hoh 1999) and xerography (Mizes et al 2000). 
Recently, investigators have reported the AFM colloid probe technique as a 
useful tool in determining variations in adhesion between pharmaceutical 
systems (Ibrahim et al 2000, Louey et al 2001, Sindel and Zimmermann 









































2001). The use of AFM to determine interactions between lactose, a common 
pharmaceutical excipient, and gelatin capsules has shown capsule 
processing to influence particle-capsule interaction (Ibrahim et al 2000). 
Additionally, disparities in the adhesive forces between a silica sphere colloid 
probe and batches of lactose tablets have been reported (Louey et al 2001). 
Furthermore, recent studies have investigated lactose-lactose interaction 
using the colloid probe technique (Sindel and Zimmermann 2001).  
 
The attachment of a micronised drug particulate to the apex of a tipless 
cantilever may be a route for the measurement of drug-drug interactions 
(cohesion) at specific humidities. Although previous studies, to investigate 
capillary interactions have been conducted using the AFM (Sedin and 
Rowden 2000, Berard et al 2002), these have generally concentrated on 
either tip-substrate interactions (Sedin and Rowden 2000) (probe/tip radius of 
curvature 20-40 nm), or larger pharmaceutical drug probe-substrate 
interactions (Berard et al 2002) (drug probe length >100 µm). The main focus 
of this investigation was to apply the colloid probe technique to micronised 
drug-drug interactions.  
 
It is important to note, that there is only a limited amount of AFM literature 
directly applicable to particle-particle interactions for inhalation therapy. The 
most relative research using micronised drug probes was published by Eve 
et al (2002) during the course of this investigation. However this focused 
more on inhaler device components, and did not investigate the influence of 
humidity.  
 
In order to quantify the behaviour of salbutamol sulphate, TAA and DSCG 
particulates in a DPI system, a study was undertaken to generate a cohesion 
profile for the micronised drugs at varied humidity using the AFM colloid 
probe technique. Because of the difficulty in conducting multiple force-
distance measurements between two individual particulates of micron size 
(1-10 µm), three techniques were developed to produce model substrates of 




Multiple force-distance curves between AFM cantilever mounted drug 
particulates and their corresponding model drug substrates were conducted 
across pre-specified areas using Force-Volume™ imaging, described in more 
detail elsewhere (Heinz and Hoh, 1999, DI Application Note).  
 
Force-Volume imaging provided a large matrix (n = 4096) of separation 
energy values at each humidity allowing comparison and statistical analysis. 
In addition, Force-Volume data provided limited, low resolution, topographical 
height data (calculated as a function of the constant compliance region), 
which could be compared to higher resolution AFM images obtained 
separately using standard tips and imaging modes (e.g. Tapping Mode™). 
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4.2 MATERIALS AND METHODS. 
 
4.2.1 Micromanipulation of Drug Particles Onto Tipless AFM 
Cantilevers. 
 
A multi-stage micromanipulation technique for the attachment of micron sized 
drug particulates to tipless cantilevers was developed/adapted from the 
method described by Preuss and Butt (1998). Briefly, a small droplet of 
epoxy resin was transferred to a clean glass cover slip and mounted on a 
custom-built microscope slide holder (Figure 4.2.1).  
 
Figure 4.2.1  Schematic diagram of the micromanipulation PTFE slide 
holder assembly 
 
The slide holder assembly was attached to a 160 X bifocal transmission 
microscope lens (Ziess, Germany) and adjusted to focus with a securing bolt. 
A tipped ‘v-shaped’ cantilever (NP20 Digital Instruments, Cambridge, UK) 
was mounted in a custom built tip holder and attached to a X,Y,Z transition 
stage. The tip was elevated into the glue and drawn along the X-axis to 
produce micron-sized protrusions. The tipped cantilever was removed and 
replaced with a, nominal 0.58 N.m-1 spring constant, tipless cantilever (DNP-












quantity of glue from a protrusion. The glass cover slip, containing glue, was 
removed from the slide holder and replaced with a clean cover slip containing 
a sample of the drug particulates. A representative micronised particle 
(approximately 2 to 5 µm) was then selected and attached to the cantilever.  
A CCD video, reflection microscope (Digital Instruments, Cambridge, UK) 
with a 500 X long working distance lens was used throughout the 
micromanipulation process to evaluate tip quality, quantity of glue, and tip 
particle integrity prior to and post curing. Prepared drug probe tips were 
stored in tightly sealed containers for 24 hours prior to use. The 
micromanipulation process is shown graphically in Figure 4.2.2. 
 
Figure 4.2.2  Photographs of the key stages of the micromanipulation 
process (cantilever length = 100µm)   
 
In addition, where possible, the colloid probes were investigated using 
scanning electron microscopy (SEM) (Jeol 6310, Jeol, Japan) at 10 KeV. 
Sample probes were mounted on carbon sticky tabs and gold-coated 
(Edwards Sputter Coater, UK) prior to imaging. It must be noted, however, 
imaging of probes using this technique was conducted at the end of a probe’s 
lifespan (i.e. on completion of the required measurements), due to the 
necessary gold coating process.  
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4.2.2 Control of Relative Humidity. 
 
The influence of relative humidity on particle substrate separation energy was 
investigated using custom-built perfusion apparatus connected to the AFM. 
Filtered nitrogen gas was split at source and passed, independently, through 
a desiccator, containing silica gel and a bubble chamber, with moisture trap. 
Both the dry and 100% humidified nitrogen were passed through separate 
needle-valve flow controllers and fed into a sealed AFM scanning head 
containing a calibrated temperature-humidity monitor (Thermo-Hygro™ 
meter, Bioforce Nanosciences Inc. Ames, USA). Total flow into the AFM 
head was approximately 1cm3 minute and was 25ºC ± 0.2ºC. Temperature of 
the humidified nitrogen was ) 25ºC to eliminate the possibility of 
condensation. A schematic representation of the perfusion apparatus is given 
















4.2.3 Preparation of Sample Substrates. 
 
In order to investigate the influence of humidity on the cohesive properties of 
the micronised drugs using the colloid probe technique, the preparation of 
fixed drug substrates was required.  Three immobilization techniques for 
such measurements were developed; (A), individual particle mounting in a 
heat sensitive polymer, (B) the use of model drug compacts formed by direct 
compression and (C) the preparation of larger (&100 µm) ‘atomically flat’ 
crystalline drug substrates with uniform flat surfaces, by controlled 
crystallisation of the original micronised material. 
 
4.2.3(a) Individual micronised particle immobilization. 
 
Micronised particle samples were immobilised on steel AFM stubs using 
Tempfix (SPI Supplies, West Chester, USA) at 40°C using a custom built 
Peltier connected to a thermocouple temperature controller (SE5000, Marlow 
Industries, Dallas, Texas). Briefly, the steel AFM sample stub was mounted 
on the Peltier and heated to 120°C. A small quantity of Tempfix was melted 
onto the stub and cooled to 40°C at which point the resin becomes tacky or 
adhesive. A small quantity of the powder was lightly brushed through a 45 
µm aperture stainless steel sieve (BS410/1986, Endecotts, London, UK) onto 
the AFM sample stub. The sieving procedure was found to remove large 
agglomerates. The AFM sample stubs, containing Tempfix-mounted 
particles, were left to cool to room temperature before removing loose 
material with a filtered nitrogen air stream. The polymer mounted drug 
samples were stored in tightly sealed containers for 24 hours prior to use. 
Utmost care was taken when handling the samples to avoid contamination. 
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4.2.3(b) Model drug compact preparation. 
 
Model surfaces from the micronised material were prepared by direct 
compression (TA HDi Texture analyser, Stable Micro Systems, Surrey, UK). 
Approximately 250 mg of micronised material was weighed into a 10 mm 
stainless steel die and compacted at a compression rate of 0.5 mm.s-1     
(500 kg, dwell time 180 seconds). Compaction profiles for each model 
compact were recorded to assess repeatability. Prepared drug compact 
surfaces were stored in tightly sealed containers for 24 hours prior to use. 
 
4.2.3(c) Atomically smooth crystalline drug substrates. 
 
Large planar surfaces of the micronised material were produced by controlled 
crystallization techniques. The precise method of crystallisation was 
dependent on the solubility profile of the specific drug. Independent solubility 
profiles and crystallisation methods were developed for salbutamol sulphate 
and TAA while the method described by Cox et al (1971) was adapted for the 
crystallization of DSCG. 
 
Solubility profiles of salbutamol sulphate and TAA in mixtures of ethanol and 
water were determined by saturating each drug in ethanol/water mixtures. 
Samples were shaken for 12 hours at 25°C (G76, Gyrotory water bath 
shaker, New Brunswick Scientific, Edison, USA) in sealed volumetric flasks. 
The saturated solutions were filtered and dried at 40°C before calculating 
solubility by mass. 
 
Salbutamol sulphate was re-crystallised by primary nucleation. A 10% w/w 
saturated solution of salbutamol sulphate in 50/50 ethanol/water was filtered 
then stirred at 20°C in a sealed crystallisation vessel. Ethanol was added at a 
rate of 15 ml.hour-1 (using a computer controlled syringe driver) until the 
solvent mass ratio was 80/20 ethanol/water. A diagrammatic representation 
of the crystallisation apparatus is shown in Figure 4.24. Recovered crystalline 






Figure 4.24 Schematic diagram of the crystallisation apparatus. Where A. 
crystallisation vessel containing water jacket, B. pump and tubing (arrows 
indicate water flow), C. temperature controlled water bath (K20, Haake, 
Karlsruhe Germany), D. Syringe and syringe driver (PHD 2000, Harvard 
Apparatus, Kent, UK), E. mechanical stirrer. 
 
Similarly, TAA was re-crystallised by primary nucleation. Briefly, a 2% w/w 
saturated solution of TAA in ethanol was filtered and stirred at 25°C in the 
sealed crystallisation vessel. Water was added at a rate of 15 ml.hour-1 until 
the solvent mass ratio was 20/80 ethanol/water. Again the recovered 
crystalline material was filtered and dried at 40°C. 
 
The method for crystallisation of DSCG was adapted from Cox et al (1971). 
Briefly, ethanol was added at a rate of 2 ml.hour-1 to an aqueous 10% w/w 
‘saturated’ solution of DSCG, until a 4:7 v/v ethanol/water mix was achieved.  
In addition, a saturated ethanol atmosphere was produced by sealing the 
apparatus in a chamber containing excess ethanol. This allowed slow 
adsorption of ethanol vapour into the aqueous solution and thus precipitated 









4.2.4 Atomic Force Microscopy. 
 
Multiple force curves for the interactions between the AFM drug probes and 
corresponding drug substrates were conducted by AFM in force volume 
mode (Multimode SPM with Nanoscope III controller, Digital Instruments, 
UK). Individual force curves (n= 4096) were conducted over a 10 µm x 10 µm 
area with the following settings; approach-retraction cycle 2 µm, cycle rate 
8.14 Hz and constant compliance region, 60 nm. The area under each curve 
was integrated using custom built batch conversion software and exported to 
produce a 64 x 64 block of separation energy values corresponding to the X 
an Y positions of the force distance curves. In addition, offline analysis of 
individual force curves was conducted, as curve shape can indicate many 
interactive physical properties (Heinz and Hoh 1999).  
 
Validation of the technique and batch conversion software was undertaken 
by conducting individual drug-probe force curve measurements on an 
atomically flat mica surface (Grade V-1 Muscovite Mica, SPI Supplies, PA, 
USA) at a range of settings (i.e. cycle rate, constant compliance force). 
 
A series of separation measurements, between the drug probes and their 
corresponding model surfaces were conducted at 15, 30, 45, 60 and        
75% RH. A new drug probe / model drug substrate were used for each 
humidity experiment. Experimental matrix details are shown in Table 4.2.1 
 
Substrate Corresponding polymer 
mounted drug particulates 
Corresponding model drug 
compact 
Corresponding  
re-crystallised substrates  
Experimental 
Humidity (% RH) 
15 45 75 15 30 45 60 75 15 30 45 60 75 
Salbutamol – 
sulphate 
Drug probe n=1 
Substrate n=5 (particles) 
Drug probe n=5 
Substrate n=5 
Drug probe n=3 
Substrate n=3 
TAA Drug probe n=1 
Substrate n=5 (particles) 
Drug probe n=5 
Substrate n=5 
Drug probe n=3 
Substrate n=3 
DSCG Drug probe n=1 
Substrate n=5 (particles) 
Drug probe n=5 
Substrate n=5 
Drug probe n=3 
Substrate n=3 
 
Table 4.2.1 Matrix for AFM drug probe-drug substrate cohesion 
measurements. 
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4.3 RESULTS AND DISCUSSION. 
 
4.3.1 Validation of the AFM Colloid Probe Technique. 
 
A scanning electron photomicrograph of a typical salbutamol sulphate, TAA 
and DSCG AFM colloid drug probes, imaged after the AFM study, are shown 
in Figure 4.3.1 (a, b and c, respectively). All of the mounted drug particulates 
used in the AFM study exhibited an approximate size 2-5 µm and were 
clearly proud of the epoxy resin on the cantilever. Care was taken during 
drug probe preparation to limit the amount of drug glue contact. Where 
possible, these observations were confirmed by SEM post analysis.  
 
However, high magnification optical microscopy (used to assess the quantity 
of glue and subsequent particle mounting process) enabled qualification of 
particle integrity, dimensions and cantilever/glue clearance (through the Z -
axis depth of field). Initially, UV light curing glue was used for particle 
mounting, as this allowed a longer ‘operator’ time scale in which to conduct 
the micromanipulation process (this approach was subsequently adopted by 
Eve et al 2002). However, a quick setting epoxy resin was finally chosen as 
this reduced the possibility of low molecular weight polymer creep and also 
avoided exposure of the organic drug materials to potentially harmful UV 
radiation. 
 
Spring constants used for the calculation of drug probe-substrate interactions 
were initially taken from the manufacturers nominal values. However, 
tolerance in AFM cantilever spring constants is a well-recognised problem as 
the spring constant is proportional to the cube of cantilever thickness (Hutter 
and Bechhoefer 1993).  In general it is believed batch-to-batch variations in 
cantilever thickness to be as great as 0.4 µm to 0.7 µm (for a standard 0.6 
µm tip). In order to reduce such batch-to-batch production variations, a wafer 








Figure 4.3.1 Scanning electron micrographs of (a) salbutamol sulphate, (b) 












Personal correspondence with Digital Instruments (DI, Cambridge, UK) 
indicated that such large variations in spring constant were significantly 
reduced between cantilevers from the same wafer (~10-20% RSD).  
Randomly chosen tips (n=5) from across the wafer indicated less than a 14% 
variance from the nominal spring constant, using the thermal method (Hutter 
and Bechhoefer 1993). 
 
Force-distance curves between a colloid drug probe and mica surface (Grade 
V-1 Muscovite Mica, SPI Supplies, PA, USA) were conducted at a range of 
settings (i.e. approach/retraction rate, Z-scan size and constant compliance 
region) to investigate the influence of controllable variables on separation 
force and energy. A mica substrate was chosen, as freshly cleaved surfaces 
were both atomically flat and free from environmental contamination. In 
addition, the planar surface of the mica eliminated variations in probe-
substrate contact geometry. 
 
Although previous studies have demonstrated specific sample rate and 
compressive force to influence force-distance curve measurements (Biggs 
and Spinks 1999), experimental validation of these settings indicated neither 
cycle time (0.1 Hz to 16 Hz for a 2 µm scan size) nor constant compliance 
loading (1 nm and 200 nm) to affect force curve measurement (Appendix 
4.1.1 and 4.1.2, respectively). However, this was not particularly unexpected 
as the micronised drugs used throughout the investigation were relatively 
brittle, crystalline materials and would not appreciably deform under stress. 
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4.3.2 Physical Characterisation of the Model Drug Substrates. 
 
In order to quantify the influence of humidity on drug cohesion, the drug 
substrates prepared using the three techniques described in section 4.2 were 
first characterized for morphology, reproducibility and stability at the 
experimental humidities. 
 
4.3.2(a) Individual micronised particle immobilization. 
 
Scanning electron photomicrographs of the salbutamol sulphate, TAA and 
DSCG, particles mounted in the Tempfix polymer are shown in Figure 4.3.2a, 
b and c, respectively).  
 
Figure 4.3.2 Scanning electron photomicrographs of (a) salbutamol 







The drug particulates were clearly embedded in the Tempfix polymer and 
appeared proud of the surface.  
 
A representative AFM Tapping Mode ‘height’ image of the salbutamol 
sulphate particles mounted in Tempfix resin is shown in Figure 4.3.3.  The 
salbutamol sulphate drug particulates had an irregular morphology and were 
clearly proud of the Tempfix polymer surface. In addition, AFM Tapping Mode 
images on randomly chosen areas of a ‘control’ Tempfix surface (not shown 
here), prepared without drug particle mounting, showed no such exposed 
irregularities. Atomic force microscope ‘height’ images for TAA and DSCG 
mounted in Tempfix produced similar results. 
 
Figure 4.3.3 Tapping Mode height profile for salbutamol sulphate particles 
mounted in Tempfix polymer. (25 x 25 µm area). 
 
Analysis of the Tempfix mounted drug particles indicated they were all within 
the particle size range as measured in Chapter 2.  
 
Representative AFM ‘amplitude response’ images of salbutamol sulphate 
and TAA at 45% RH are shown in Figure 4.3.4 (a and b, respectively). It can 
be seen from Figure 4.3.4(a) that salbutamol sulphate exhibits a columnar 
shape while TAA (Figure 4.3.4(b)) appears to have a more flattened platelet 
morphology. Similar low magnification AFM images of DSCG suggested a 
columnar shape.  In general, the low magnification AFM images agreed well 
5µm
77 
with studies of the micronised drugs using low temperature scanning electron 
microscopy (Chapter 2). 
 
Both salbutamol sulphate and TAA showed no macroscopic changes in 
particle morphology over the humidity range 15-75% RH. In comparison, the 
morphology of DSCG clearly changed as humidity was increased from 15 to 
75% RH suggesting sorbed moisture to integrally influence particle 
morphology. Representative high-resolution AFM images (amplitude 
response) of a DSCG particle after exposure to 15, 45 and 75% RH (for 
approximately 4 hours at each humidity) is shown in Figure 4.3.4c. 
 
Variations in particle morphology of the micronised DSCG with respect to 
relative humidity were not unexpected however, and such observations 
correlated well with the large moisture sorption and variation in X-ray powder 
diffraction pattern across the humidity range (Chapter 2).  
 
As previously discussed, DSCG is effectively a nematic choromonic liquid 
crystal that below 93% RH forms a solid solution (Cox et al 1971, Hartshorhe 
and Woodard 1973, Chen et al 1999). In essence, the planar cromoglycate 
molecules are ‘stacked’ to form long rods that in turn form an interstitial solid 
held together by water molecules. These water channels can subsequently 
contain up to approximately 9 molecules of water per unit cell before 
collapsing to form a liquid crystal mesophase (at 93% RH) (Cox et al 1971, 
Hartshorhe and Woodard 1973, Chen et al 1999). 
 
Adsorption or de-sorption of water molecules into the crystal structure will 
subsequently cause changes in the torsional angles of the cromoglycate 
molecules (Cox et al 1971, Hartshorhe and Woodard 1973, Chen et al 1999), 
resulting in a variation in the unit cell dimensions. Consequently it is likely 
that such a change in crystal structure with respect to humidity would have a 
significant impact on the macroscopic particle morphology. 
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Figure 4.3.4 Atomic force microscope images of micronised drug particles 
mounted in Tempfix polymer: (a) salbutamol sulphate (45% RH), (b) TAA 
(45% RH) and (c) DSCG (taken at 15,45 and 75% RH). 
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4.3.2(b) Model drug compact preparation. 
 
Compaction profiles for salbutamol sulphate, TAA and DSCG are shown in 
Figure 4.3.5 (a, b and c, respectively). All three micronised drugs showed 
similar compaction profiles, and produced relatively brittle model compacts 
with smooth planar surfaces present on the dye faces (observed under an 
optical microscope). 
 







However, AFM (Tapping Mode) height images of the salbutamol sulphate, 
TAA and DSCG model compacts shown in Figure 4.3.5 (a, b and c, 
respectively) suggested an irregular surface morphology.  
 
Figure 4.3.6 Representative AFM Tapping Mode ‘height’ images of the 





Root mean square roughness (Rrms) values for each sample were calculated 











  Equation 4.3.1 Rrms roughness calculation. 
 
Where n is the number of points in topography profile and yi is the distance of 
a point i from the centre line. Root mean square roughness values (10 µm x 




Salbutamol sulphate 101 nm ± 16 nm 
TAA 171 nm ± 10 nm 
DSCG 143 nm ± 9 nm 
 
Table 4.3.1 Root mean square roughness analysis of the model drug 
compacts (n=5).  
 
All the drug model compact Rrms values were of similar magnitude. However, 
there was a statistically significant variation (ANOVA, p<0.05) between the 
compacts prepared from the different micronised drugs. This was not 
unexpected, however, and is most likely attributable to the variation in initial 
particle size (Chapter 2).  
 
Tapping Mode AFM analysis of the three micronised drug compacts at 15, 45 
and 75% RH indicated humidity to have no influence on salbutamol sulphate 
or TAA compact morphology. However, minor variations in the surface 
morphology of the DSCG compacts were observed when the humidity was 








Figure 4.3.7 Representative AFM height images of the DSCG model 
compact taken at (a)15% RH, (b) 45% RH and (c) 75% RH. 
 
In addition, root mean square roughness analysis of DSCG compacts 
showed a decrease in the mean Rrms as humidity was increased to 75% RH, 





4.3.2(c) Atomically smooth drug substrates. 
 
The solubility curve for salbutamol sulphate and TAA in mixtures of 
ethanol/water is expressed graphically in Figure 4.3.8 (a and b, respectively).  
 
 
Figure 4.3.8  Solubility curves for (a) salbutamol sulphate and (b) 
TAA. 
 
Re-crystallisation of salbutamol sulphate was controlled by adding ethanol as 
an anti-solvent. A saturated solution of salbutamol sulphate was prepared by 
adding 10.08 g of material to a 50/50% w/w ethanol/water mixture (calculated 
from the solubility curve shown in Figure 4.3.8). This should yield a 
theoretical recovery mass of 7 g at an 80/20 ethanol/water ratio. Recovered 




Re-crystallisation of TAA was controlled by adding 100 g of water (as an anti-
solvent) to a saturated solution of TAA in 25 g ethanol (1.894% w/w). 
Solubility of TAA in a 20/80 ethanol/water mix was 0.032% w/w and therefore 
should produce a theoretical yield of 0.433 g. Recovered crystal mass was 
0.431 g indicating a recovery efficiency of 99.5%. 
 
Recovery of DSCG after crystallisation for over a one week period suggested 
a low recovery efficiency (<50%). Samples were extracted by filtration and 
were washed with ethanol. The low recovery efficiency is most likely due to 
the relative solubility of the ethanol water mixture, with a large proportion of 
the DSCG remaining in solution or in a liquid crystal mesophase. However 
the recovered crystals appeared needle like as previously reported by Cox et 
al (1971) and had suitable dimensions for force volume measurements.  
 
Representative scanning electron micrographs of the re-crystallised 
salbutamol sulphate, TAA and DSCG are shown in Figure 4.3.9 (a, b and c, 
respectively).  
 
Salbutamol sulphate SEM images (Figure 4.3.9a) had a needle like 
morphology with relatively smooth undamaged surfaces. In comparison TAA 
crystals appeared to have a tabular shape. 
 
Scanning electron micrographs of the DSCG (Figure 4.3.9c) had a columnar 
needle like shape with smooth planar surfaces. However, the scanning 
electron microscopy process resulted in very apparent damage to the crystal 
surface, with the long axis of the crystal appearing to split into fragments. It is 
suggested that the necessary vacuum in combination with the relatively high 
energy electron beam (10 Kev acceleration voltage) ‘pulled’ the interstitial 
water molecules from the crystal structure. Such damage to the crystal 
structure can clearly be seen in Figure 4.3.9c. Low temperature SEM 
(LTSEM) may provide a means of reducing such artefacts, and clearly 




Figure 4.3.9 Representative SEM images of re-crystallised (a) salbutamol 






Atomic force microscope (Tapping Mode) images of the salbutamol sulphate, 
TAA and DSCG model compacts (Figure 4.3.10a, b and c, respectively) 
suggested smooth planar crystal surfaces with minimum surface defects. 
 
Figure 4.3.10  AFM height (with corresponding amplitude response) 









Analysis of the salbutamol sulphate AFM image (Figure 4.3.10a) showed a 
clear distinction between two crystal faces due to the clear edge and 
variation in surface angles. 
 
Literature values indicate the crystalline structure of salbutamol sulphate had 
a monoclinic crystal system with a * angle of 81.19° (Leger et al 1978). 
Cross sectional analysis of the AFM topographical data, taken perpendicular 
to the edge between the two faces, indicated an apparent angle of 99°. This 
correlated well with the consecutive angle of * (98.81°.), suggesting the 
image was taken between the {001} and {100} crystal faces. Subsequent 
force volume measurements between salbutamol sulphate drug probes and 
the salbutamol sulphate crystal surfaces were conducted at random on the 
{001} and {100} crystal faces. 
 
Again, Tapping Mode images of TAA, allowed clear distinction between 
crystal faces (Figure 4.2.10b), however, limited literature regarding the   
crystallographic structure of TAA did not allow distinction between faces. 
Although this clearly warrants further investigation, the production of suitable 
crystals for X-ray crystallographic studies is complicated and the facilities for 
such determinations were not readily available. Subsequently such 
investigations were deemed outside the scope of this research.  
However, in order to maintain experimental consistency, the most dominant 
face was chosen as a substrate for force volume measurements. 
 
As with salbutamol sulphate crystals, Tapping Mode images of DSCG 
showed a clear distinction between two distinct crystal faces (along the a axis 
or length of the crystal (Chen et al 1999)). Cross sectional analysis of the 
AFM topographical data, taken perpendicular to the two faces indicated 
apparent angles of around 107° - 120°. This corresponds well to previously 
reported values of 120° (Cox et al 1971) for the Triclinic DSCG crystal +-
angle (Chen et al 1999). However variations will exist due to the number of 
water molecules present in the unit cell (crystal expansion). In addition, no 
variation in surface morphology (of the individual crystal faces) was observed 
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with respect to humidity. Such observations are to be expected, however, as 
torsional rearrangement of the DSC molecule occurs in the internal structure 
and therefore may not result in a directly visible surface effect. Subsequent 
force volume mode measurements were conducted at random on either face 
along the crystal length. 
 
Atomic force microscopy Rrms roughness analysis of salbutamol sulphate, 
TAA and DSCG images are tabulated below (Table 4.3.2). 
 
Drug Rrms 
Salbutamol sulphate 3.6 nm ± 2.0 nm 
TAA 1.7nm ± 0.8 nm 
DSCG 5.4 nm ±1.5 nm 
 
Table 4.3.2  Root mean square roughness analysis of the re-crystallised 
model drug surfaces (n=5). 
 
As expected, crystals of all three drugs exhibited roughness parameters one 
order of magnitude less than that for their corresponding model compacts. 
Essentially, the roughness values correspond to an atomic level contiguity, 
as the majority of variations in morphology on a particular crystal plane would 
be due to the unit cell crystal growth boundaries (e.g. the linear striations 
observed on the lower crystal plane of the AFM salbutamol sulphate 
amplitude image in Figure 4.3.10a). 
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4.3.3 Atomic Force Microscope Drug Probe Cohesion Measurements. 
 
In order to understand the influence of humidity on particle-particle 
interactions a series of cohesion profiles were constructed for salbutamol 
sulphate, TAA and DSCG on a series of model drug substrates.  
 
4.3.3(a) AFM on polymer mounted particulates. 
 
The influence of humidity on drug particle cohesion was investigated by 
conducting FV scans (25 µm2) between a drug probe and corresponding drug 
particles mounted in Tempfix polymer resin. 
  
An example of a force volume scan, conducted between a salbutamol 
sulphate drug probe and salbutamol sulphate mounted particles is shown in 
Figure 4.3.11. The white areas on the FV ‘relief’ height image correspond to 
regions with a Z-axis height of greater than 2.5 µm. It would be reasonable to 
assume that such undulations in the surface could be identified as 
micronised drug particles, as they correspond to observations made using 
conventional AFM tips and imaging methods (Figure 4.3.3). Comparison of 
the ‘relief’ height image with the FV image (Figure 4.3.11) suggested the 
raised ‘drug particle’ areas have a low adhesion force in comparison to the 
polymer surface. A representative force curve for the salbutamol sulphate 
interactions is included in the FV scan with its relative position marked with a 







Figure 4.3.11  Force volume data for salbutamol sulphate drug probe 
interactions with salbutamol sulphate particles mounted in Tempfix. 
 
In order to quantify such drug probe interactions, randomly chosen force 
curves taken across five distinct ‘raised particle’ regions were exported and 
manually integrated to obtain both cohesion force and separation energy 
values. This procedure was repeated at each humidity. Furthermore, a series 
of force curves taken on the Tempfix polymer resin was exported for 
comparison. 
 
It is important to note that although an individual analysis approach does not 
allow such comprehensive statistical analysis as batch reprocessing, it was 
deemed necessary to ensure definition between micronised particle and drug 
Tempfix polymer interactions. 
 
A summary of the salbutamol sulphate, TAA and DSCG cohesive forces are 
given in Appendix 4.2, while separation energies are given in Appendix 4.3. 
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Analysis of Cohesion Forces. 
  
ANOVA one-way analysis of variances indicated humidity to have a 
significant influence (p<0.05) on the cohesion force of all three micronised 
drugs with respect to humidity. However such an observation is effectively 
dependent on a normal distribution. Further analysis of the cohesion force 
data (Appendix 4.2) suggested this not to be the case as the large standard 
deviations and positive skewness values indicated a non-normal distribution. 
Analysis of the cohesion force values indicated a lognormal distribution to 
best fit the data. The use of log normal distributions to describe such data is 
well documented and can be found in abundance in the literature. A good 
overview, explaining the fundamentals and treatment of such data can be 
found in Hinds 1999 
 
In general, the force distance curve ‘anatomy’ for salbutamol sulphate agreed 
with previously published data using the AFM colloid probe technique (Eve et 
al 2002). However, values calculated for salbutamol sulphate cohesion were 
two orders of magnitude less than reported by Eve et al (2002). Critical 
review of this previously reported work indicated that the wrong cantilever 
spring constants were used for calculation of adhesion force. Values of ~70 
N.m-1 were used for measurements using pyramidal tipless cantilevers 
(clearly shown in the accompanying Figures), which usually have nominal 
spring constants of around 0.6 N.m-1. As Tapping Mode tips with high aspect 
ratio probes are quoted as having spring constants of around 70 N.m-1 
(Correspondence with Digital Instruments, Cambridge, UK) it is envisaged 
that the wrong spring constants were used for calculating adhesion force. 
Subsequent analysis of the force curves published by Eve et al (2002) using 
a ‘corrected’ spring constant of 0.6 N.m-1 would give equivalent cohesion 
values to this investigation. No such literature relating to fundamental 
cohesion measurements on DSCG or TAA could be found. 
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Analysis of lognormal probability plots of salbutamol sulphate, TAA and 
DSCG using Minitab statistical analysis software (Minitab Inc. PA, USA) 
suggested humidity to have a significant influence (CI = 0.95) on the 
cohesion force.  
 
The median adhesion force (f0.5) for salbutamol sulphate increased with 
respect to humidity (32.9 nN, 48.5 nN and 58.7 nN for 15, 45 and 75% RH, 
respectively) suggesting capillary interactions to become more dominant at 
higher humidities. Such observations correlate well with previous in-vitro 
investigations, which demonstrated a decrease in salbutamol sulphate fine 
particle aerosolisation as humidity was increased (Jashnani and Byron 1995, 
Jashnani et al 1996).  
 
Comparison of both the mean and median salbutamol sulphate cohesion 
values with Tempfix adhesion measurements suggested the polymer-drug 
adhesion to be significantly greater than drug cohesion. All adhesion 
measurements conducted between the ‘flat’ polymer regions of the FV scan 
were of a higher value than that of salbutamol sulphate cohesion (142.1 nN, 
152.6 nN, 164 nN at 15, 45 and 75% RH, respectively). Such observations 
are to be expected however, as adhesive resins have high surface energies 
due to the polar nature of groups present on the polymer chains (Pizzi and 
Mittal 1994). 
      
In contrast to the salbutamol sulphate cohesion profile, the median 
separation force for TAA decreased as humidity was raised  (61.2 nN, 30.6 
nN and 19.9 nN for 15, 45 and 75% RH, respectively). One possible 
explanation for such a profile would be the presence of dominant electrostatic 
forces at lower humidities. Analysis of Individual TAA force-piezo distance 
curves taken at 15 and 75% RH are shown in Figure 4.3.12 (a and b, 
respectively).  At low humidity (Figure 4.3.12a) a negative curve in cantilever 
deflection as a function of piezo displacement suggests a long-range 
attraction force to be acting over the Z-scan axis (2 µm). It is reasonable to 





Figure 4.3.12  Influence of humidity on the force piezo-distance curve 
anatomy of TAA at (a) 15% RH and (b) 75% RH. 
 
As humidity was increased to 75% RH (Figure 4.3.12b), the presence of such 
a long-range attraction force was not observed. Again this would be expected 
from an electrostaticly charged material, as progressive sorption of water at 
high humidities would increase surface electron mobility and hence dissipate 
charge.   
 
As with salbutamol sulphate, the adhesion between TAA and Tempfix 
polymer resin was greater than the cohesion force in all cases (113.6nN, 
349.1nN and 470.2nN at 15 45 and 75% RH). Again this was expected, 
however, it is interesting to note that the TAA-Tempfix adhesion increases 





The cohesion force for DSCG at 15% RH was greater than salbutamol 
sulphate and TAA at equivalent humidity. Furthermore, the 10th percentile 
values at 15% RH were greater than the median adhesion force for both 
salbutamol sulphate and TAA. Such observations may be due to the 
presence of water in the crystal structure (>5%, Chapter 3) leading to 
elevated capillary interactions at relatively low humidities. 
 
Increasing the humidity from 15% RH to 45% RH resulted in an increased 
median cohesion force from 55.0 nN to 98.4 nN. By normalising the data, it 
becomes clear that the relative increase/decrease in cohesive forces for 
DSCG is greater than salbutamol sulphate and TAA, with a +78.8% increase 
between 15 and 45% RH for DSCG in comparison to +47.6% and -67.5% for 
salbutamol sulphate and TAA over the same humidity range. This increase 
can most likely be attributed to further water absorption in combination with 
surface morphological changes of both the drug probe and Tempfix mounted 
particles. 
 
Elevation of humidity from 45 to 75% RH resulted in discontinuous FV 
measurements for DSCG interactions. Essentially, the force-piezo distance 
curves conducted between the DSCG drug probe and micronised particles 
became erratic, with multiple break points being observed during the 
retraction cycle of individual measurements. Such observations continued 
throughout the scan until the approach and retraction cycles were ‘separated’ 
lines with no observed constant compliance region. This was indicative of 
drug probe loss, since the tipless cantilever surface will produce a contact 
area far greater than the spring constant tolerance.      
 
Subsequent observation of the DSCG drug probe tip, using optical 
microscopy, indicated the micronised drug to be ‘lost’. It is envisaged that 
such a loss may be due to morphological changes of the drug probe as water 
is absorbed into the crystal lattice. Furthermore, as DSCG is an interstitial 
solid, effectively held together by water molecules, the adhesion force 
between the individual drug particles may become great enough to ‘tear’ 
apart or fracture the crystal lattice. Consequently, the cohesion force 
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between DSCG particles could only be investigated by the AFM colloid probe 
technique at 15 and 45% RH. 
 
As with salbutamol sulphate and TAA the median separation force for DSCG-
Tempfix was greater than the cohesion force in all cases (110.1 nN and 
136.8 nN for DSCG-Tempfix interactions at 15 and 45% RH, respectively). 
  
Analysis of Cohesion (Separation) Energy. 
 
By integration of the piezo-displacement cantilever deflection curve, the 
energy of separation (esep) between a drug probe and surface can be 
obtained. The advantage of expressing particle interactions in terms of esep is 
that it takes into account the variations in mechanical properties of the two 
contacting surfaces. Although the force of adhesion/cohesion allows us 
insight into the influence of physico-chemical properties, roughness and 
environmental conditions on the interactive mechanisms of two surfaces, it 
does not directly take into account the elastic moduli of the contacting 
surfaces. A graphical representation of the cohesion energy data values for 
all three drugs, as a function of humidity, is given in Figure 4.3.13. 
 
As with the cohesion force values, a positive skew in the separation energy 
was observed suggesting irregular morphology to produce a lognormal 
separation energy distribution. Again, as with the cohesion force 
measurements the influence of humidity had a similar significant impact on 
the cohesion profile of each drug. An increase in median separation energy 
was observed for salbutamol sulphate (853.0 nJ, 1603.9 nJ and 2786.5 nJ at 
15, 45 and 75% RH, respectively) and DSCG (2623.4 nJ and 8271.7 nJ), 
while a decrease was observed for TAA (2308.9 nJ, 571.5 nJ and 259.5 nJ). 
Comparative analysis between force and separation energy values as a 
function of humidity suggested good correlation. However, significant 
differences (ANOVA p<0.05) in the force-energy factors were observed (for 
salbutamol sulphate and TAA) suggesting, as expected, the presence of 




Figure 4.3.13  Distribution of separation energy values (cohesion) 
between individual salbutamol sulphate, TAA and DSCG particulates. 
 
Consequently it was decided to focus primarily on separation energy values 
and not separation force. 
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4.3.3(b) AFM on model drug compacts. 
 
The limitations of individual particle analysis were overcome by the 
preparation of large planar surfaces of the drug materials by direct 
compression. Force piezo-distance curves were conducted using the AFM in 
Force volume mode, over 10 µm x 10 µm areas of the model compacts and 
were batch reprocessed to obtain a block of 64 x 64 (4096) separation 
energy values corresponding to the relative position of each measurement. 
  
Separation energy measurements between five salbutamol sulphate drug 
probes and salbutamol sulphate model compacts were investigated by AFM 
at 15, 30, 45, 60 and 75% RH and are summarised in Appendix 4.4.  
 
As with individual particle-particle measurements, integration of the force 
distance curves measured over a 10 µm x 10 µm area (n=4096) produced a 
relatively wide distribution of separation energy values, with calculated 
standard deviations being of equivalent value to the mean (RSD 67 to 112% 
across the humidity range). Furthermore, separation energy histogram 
analysis showed the data spread across more than one order of magnitude in 
an asymmetrical, positively skewed distribution.  
 
As expected, cumulative frequency-log distributions of the separation energy 
values indicated a lognormal distribution. This is demonstrated in Figure 
4.3.14 as cumulative frequency log-separation energy values for salbutamol 
sulphate drug probe 1 (15 - 75% RH).  
 
Cumulative frequency-log distributions for four further drug probe-compact 
measurements can be found in Appendix 4.5. The assumption of lognormal 
distribution was further justified using apparent linear regression analysis of 
log-probability plots (5 - 95%) where R2 values of & 0.94 were obtained (an 






Figure 4.3.14  Separation energy distribution for salbutamol sulphate 
drug probe on salbutamol sulphate model surface at 15, 30, 45, 60 and       
75 %RH at 25°C ± 0.2°C, (n=4096). 
 
 Figure 4.3.15  Example of a cumulative probability plot for salbutamol 
sulphate tip 1 on salbutamol sulphate model surface at " 15% RH, ! 30% 
RH, " 45% RH,     ! 60% RH and # 75% RH. Dotted lines indicate 
apparent linear fit (5-95 % probability data). 
. 


















As a result, a median value, or 50% cumulative undersize (e0.5), was selected 
as the most appropriate descriptor for separation energy measurements 
between AFM drug probes and model compacts, since the large positive 
skew in the data may adversely affect the mean values.  
 
Analysis of the separation energy data block (64 x 64 force curves) 
suggested no relationship between force curve number and separation 
energy value. In addition, offline analysis of individual force curves conducted 
at the beginning, middle and end of each run indicated no rank change in 
separation energy value or curve shape. Such observations would suggest 
that the salbutamol sulphate drug probe did not deform or appreciably 
tribocharge under such conditions.  Furthermore, comparison of the 
separation energy data block values with the individual force curves, in offline 
analysis, indicated no surface ‘hotspots’ that may have been observed if 
contamination was present.   
 
The influence of humidity on the e0.5 for salbutamol sulphate-compact 
interactions is shown graphically in Figure 4.3.16. In all cases, change of 
humidity had a significant affect on the e0.5 (CI = 0.95). Furthermore, a 6.4 ± 
0.9 times increase in e0.5 (n=5) occurred between 15 and 75% RH indicating 
















Figure 4.3.16  Influence of humidity on the median (e0.5) separation 
energy values for salbutamol sulphate drug probes on model compact 
salbutamol sulphate surfaces. Centre line for each bar indicates median; 
upper and lower bars indicate upper and lower confidence intervals (CI = 
0.95). 
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Separation energy measurements between five TAA drug probes and TAA 
model compacts, at 15, 30 45, 60 and 75% RH are summarized in Appendix 
4.6. 
 
Again, a large positive skew in separation energy values were observed, 
suggesting a lognormal distribution. Cumulative frequency log-separation 
energy values for TAA drug probe 1 at 15 - 75% RH is shown in Figure 
4.3.17. Additionally, cumulative frequency-log distributions for the remaining 
four TAA drug probe-compact measurements can be found in Appendix 4.7.  
 
 
Figure 4.3.17  Separation energy distribution for TAA drug probe 1 on 
salbutamol sulphate model surface at 15, 30, 45, 60 and 75 %RH 
at 25°C ± 0.2°C, (n=4096). 
 
Again the assumption of lognormal distribution was justified using apparent 
linear regression analysis of log-probability plots (5-95%) where R2 values of 




Figure 4.3.18  Example of a cumulative probability plot for TAA tip 1 on 
a TAA model compact surface at " 15% RH, ! 30% RH, " 45% RH, ! 60% 
RH and # 75% RH. Dotted lines indicate apparent linear fit.(5-95% 
probability data). 
 
As with the salbutamol sulphate drug probe-compact interactions, offline 
analysis of the force-distance curves indicated no correlation between run 
number and separation energy value, but a clear variation in separation 
energy as function of humidity. As with the individual TAA particle-particle 
interactions (investigated in section 4.3.3a), an increase in humidity resulted 
in an overall decrease in separation energy. As previously discussed, this is 
most likely attributed to the dissipation of electrostatic forces. Again, this was 
qualitatively confirmed by the offline analysis of individual force-distance 
curves. As expected, a clear variation in force-distance curve anatomy was 
observed at different humidities (as was observed for TAA particle-particle 
interactions at low humidity show in Figure 4.3.12b). At lower humidities (ca. 
15-30% RH) a clear long-range attraction force was observed between the 
TAA drug probes and TAA model compacts suggesting electrostatic 
attraction. This long-range attraction was not observed at higher humidities 
(ca. 45-75% RH). 
 


















The influence of humidity on the e0.5 for TAA drug probe-compact interactions 
is shown graphically in Figure 4.3.19. In all cases, change of humidity had a 
significant affect on the e0.5 (CI = 0.95). A 2.3 ± 0.3 times decrease in e0.5 
(n=5) occurred between 15 and 75% RH indicating electrostatic forces to be 
a dominating factor at lower humidities, with the presence of moisture at 
higher humidities potentially dissipating such interactions.  
 
 
Figure4.3.19   Influence of humidity on the median (e0.5) separation 
energy values for TAA drug probes on model TAA surfaces. Centre line for 
each bar indicates median; upper and lower bars indicate upper and lower 
confidence intervals (CI = 0.95). 
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Separation energy values obtained from DSCG drug probe measurements 
on DSCG model compact surface measurements are summarized in 
Appendix 4.8. Cumulative frequency log-separation energy values for DSCG 
drug probe 1 at 15 - 60% RH is shown in Figure 4.3.20. Additionally, 
cumulative frequency-log distributions for the remaining four DSCG drug 
probe-compact measurements can be found in Appendix 4.9. 
 
Figure 4.3.20  Separation energy distribution for DSCG drug probe 1 on 
a DSCG model surface at 15, 30, 45,60 and 75% RH at 25°C ± 0.2°C, 
(n=4096). 
 
A large statistically significant (CI = 0.95) increase in the median separation 
energy (e0.5) with respect to humidity was observed for all five DSCG drug 
probe investigations. Furthermore, an increase in humidity from 60 to 75% 
RH resulted in the loss of the drug probe from the cantilever, thus making 
measurement impossible (confirmed by optical microscopy). Such 
observations are in good correlation with those made for individual particle-
particle investigations, with particle loss occurring between 45 and 75% RH. 
As discussed, the loss of the drug probe from the cantilever at humidities in 
excess of 60% RH may be related to the change in particle morphology (as 
observed in Chapter 4.3.2, Figure 4.3.7). 
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As with the salbutamol sulphate and TAA model compact measurements, the 
model compact separation energy profile for DSCG exhibited a wide 
lognormal distribution. However, analysis of the ‘apparent’ linear fit 
suggested the separation energy values were not as regularly distributed. 
This was highlighted by the low R2 values (0.700 to 0.968) shown in 
Appendix 4.8. An example of the linearity analysis is shown in Figure 4.3.21. 
In addition, a variation in the slope was observed for DSCG probes at various 
humidities, however this was not reproducible and could therefore not be 
statistically investigated. Again, this may be due to unpredictable variation in 
morphology in combination with the large water sorption. 
 
Figure 4.3.21  Example of a cumulative probability plot for DSCG tip 1 
on a DSCG model compact surface at " 15% RH, ! 30% RH, " 45% RH,  
! 60% RH and # 75% RH. Dotted lines indicate apparent linear fit.(5-95%  
probability data). 
 
The influence of humidity on the e0.5 for DSCG drug probe-compact 
interactions is shown graphically in Figure 4.3.22. In all cases, change of 
humidity had a significant affect on the e0.5 (CI = 0.95). An 11.1 ± 6.0 times 
increase in mean e0.5 (n=5) occurred between 15 and 60% RH indicating 
capillary forces to dominate DSCG interactions. 
  


















Figure 4.3.22  Influence of humidity on the median (e0.5) separation energy 
values for DSCG drug probes on model DSCG surfaces. Centre line for each 
bar indicates median; upper and lower bars indicate upper and lower 
confidence intervals (CI = 0.95). 
 
The spread in separation energy values for each of the micronised drug 
probe measurements can be determined from the geometric standard 













GSD        Equation 4.3.2. 
Where ex are the respective percentile values for the lognormal distribution. 
Essentially a GSD of one would be a monomodal, monodispersed separation 
energy distribution (Hinds, 1999).  Analyses of GSD values for each drug 
probe compact investigation are plotted as a function of humidity and are 
shown in Appendix 4.10. Statistical analysis of salbutamol sulphate and TAA 
drug probe-model drug compact surface interactions indicated no statistical 
variation (ANOVA p<0.05) in GSD with respect to humidity. In comparison, a 
statistically significant variation in GSD for DSCG interactions was observed. 
Again this is most likely attributed to variations in morphology with respect to 
humidity. 
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4.3.3(c) AFM on atomically flat crystalline material. 
 
It is clear that separation energy measurements, conducted between 
micronised drug probes over large areas of compacted model drug 
substrates, allows the collection of valuable data that may be applied to bulk 
material properties. However, the relatively rough surfaces produced by 
direct compression (under these experimental conditions) resulted in large 
separation energy distributions. Although this may be an accurate 
representation of the separation energy distributions that will be observed 
between individual particulates (as observed previously), it would be 
interesting to eliminate the influence of substrate roughness on drug probe 
interactions. 
 
Subsequently, a series of ‘atomically smooth’ surfaces were produced by 
controlled crystallisation. Essentially, this produced a series of model drug 
substrates that contained roughness parameters of a similar order to that of 
the crystal unit cell. It is reasonable to conclude, therefore, that such surfaces 
would not contain large irregularities in morphology resulting from subjection 
to rapid precipitation or micronisation.  
 
Separation energy measurements, conducted at 15, 30, 45, 60 and 75% RH, 
between salbutamol sulphate, TAA and DSCG drug probes with their 
corresponding re-crystallised surfaces are summarised in Appendix 4.11, 
4.12 and 4.13, respectively.  
 
Residual low-resolution height images, produced from the 60 nm constant 
compliance threshold during force-volume analysis, indicated the surfaces to 
be smooth with clear angles relating to the change in crystal plane (similar to 
the high resolution Tapping Mode images shown in Figure 4.3.10). An 
extreme example for salbutamol sulphate drug probe measurements is 
shown in Figure 4.3.23a, where 3 crystal planes intersect. Separation energy 
values conducted over the same region was exported as a 64 X 64 block of 
data (relating to the X and Y positions each force-distance curve was taken) 
and is shown in Figure 4.3.23b. Clear variations in the separation energy 
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values could be directly related to the low-resolution height data, which was 
collected simultaneously. The majority of the separation energy values were 
of similar magnitude and were obtained from the two large crystal planes. A 
second lower set of energy values were obtained on the smaller acute angled 
plane. Finally a third high energy set of data points were obtained at the 
intersection between the two large crystal planes (Figure 4.3.23).  
 
Figure  4.3.23 (a) Low resolution height image produced from force-
volume measurements of salbutamol sulphate drug probe measurements on 
a re-crystallised salbutamol sulphate surface. (b) Separation energy 
distribution for as a function of colloid probe position on the same region of 




By comparing the separation energy values obtained over a 64 µm X 64 µm 
region to the corresponding height image (Figure 4.3.23) it becomes clear 
that the surface morphology and structure of the crystal will play an important 
role on the cohesion characteristics. The separation energies for salbutamol 
sulphate drug probe measurements obtained on the three intersecting crystal 
planes can be shown clearly when plotted as a frequency distribution (Figure 
4.3.24).   
 
 
Figure 4.3.24  Frequency distribution for salbutamol sulphate drug 
probe measurements on the same region of the salbutamol sulphate re-
crystallised surface as shown in Figure 4.3.23. 
 
Separation energy measurements between all the drug probes and 
corresponding re-crystallised surfaces were conducted on large 10 µm X    
10 µm areas of the apparent dominant crystal face. In general, intersections 
between crystal planes were not observed during this process, as the 
position of the drug probe in relation to the crystal could be controlled visually 
prior to analysis. However, regions where such intersections occurred were 
analysed, in a similar manner to that in Figure 4.3.23, where separation 
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energy values that did not correspond to the dominant plane were removed 
manually offline. This produced, a separation energy distribution for 
interactions between a drug probe and the ‘apparent’ dominant face of its 
corresponding crystal. 
 
Representative cumulative separation energy distributions for measurements 
between a salbutamol sulphate, TAA and DSCG drug probe and 
corresponding crystal surface are shown in Figure 4.3.25 (a, b and c, 
respectively). In addition, two further replicate probe measurements were 
conducted for each drug material and are shown in Appendix 4.14. 
 
For comparative purposes the cumulative separation energy distributions are 
plotted on the same scale as that for drug probe compact measurements 
(Figure 4.3.14, 4.3.17 and 4.3.20). Unlike the drug probe model compact 
measurements, narrow distributions in separation energy values were 
observed for each of the drug probes. This can be clearly observed by the 
sharp ‘cut-off’ in the cumulative separation energy plots (Figure 4.3.25). 
Furthermore, low GSD and RSD values indicated a mono-modal, normally 
distributed separation energy for each of the drug probe crystal interactions. 
 
Such observations are not unexpected however, as the drug probe 
interactions were conducted on one face of an ‘atomically flat’ crystal and 
would therefore, theoretically produce one separation energy. The 
assumption of a normal separation energy distribution was further 
investigated by linear regression of normal probability plots (examples of 
which are given in Figure 4.3.26). As expected, linear regression indicated a 
R2 & 0.903 across salbutamol sulphate and TAA drug probe measurements 
(DSCG produced lower R2 values at high humidity), suggesting a normal 
distribution. Subsequently, data for drug probe-crystal interactions were 




Figure 4.3.25  Separation energy distribution for (a) salbutamol 
sulphate, (b) TAA and (c). DSCG drug probe interactions on their 





Figure 4.3.26  Examples of the normal linear fit for (a) salbutamol 
sulphate, (b) TAA and (c) DSCG separation energy measurements on their 





The influence of humidity on the separation energy profiles for salbutamol 
sulphate, TAA and DSCG on their corresponding re-crystallised surfaces 
suggested similar trends to that observed for individual particle-particle and 
particle-model drug compact investigations. Mean (± Std) values for 
salbutamol sulphate, TAA and DSCG drug probe crystal interactions are 
shown graphically in Figure 4.3.27. 
 
A 3.0 ± 2.2 increase in mean separation energy for salbutamol sulphate drug 
probe interactions were observed between 15 and 75% RH. Statistical 
analysis (ANOVA, Fisher pairwise p<0.05) suggested this observation to be 
significant across all humidities for all salbutamol sulphate drug probes (n=3).  
As previously discussed this may be due to an increase in capillary forces at 
higher humidities as water is adsorbed on the drug probe and crystal 
surfaces. 
 
As with the particle-particle and particle-compact measurements, TAA drug 
probe interactions with TAA crystalline surfaces suggested a small but 
statistically significant decrease (1.1 ± 0.1 times) in separation energy 
(ANOVA, p<0.05) as humidity was increased (15 - 75% RH). In addition, 
Fisher pair wise analysis indicated that increased humidity caused a 
significant (p<0.05) decrease in at each humidity for all drug probes with the 
exclusion of drug probe three (Appendix 4.12) between 30 and 45% RH. 
Again, long-range attractive forces were observed at low relative humidities 
suggesting the presence of an electrostatic attraction mechanism. 
 
As expected analysis of the DSCG drug probe-crystal separation energy 
profile showed large statistically significant increase (ANOVA p<0.05) in 
separation as humidity was raised. In general, a 3.3 ± 0.3 times increase in 
separation energy was observed for three drug probe crystal interactions, 
between 15 and 60% RH, again suggesting sorption of water into DSCG to 





Figure 4.3.27  Mean separation energy values (± standard deviation) 
for (a) salbutamol sulphate, (b) TAA and (c) DSCG interactions with their 





4.4 CONCLUSIONS: ATOMIC FORCE MICROSCOPE COHESION 
MEASUREMENTS. 
 
The AFM colloid probe technique has been successfully developed to 
measure separation energies for three micronised drugs as a function of 
humidity. Clear variations in ‘cohesion profiles’ for salbutamol sulphate, TAA 
and DSCG were observed. In general, the energy to separate salbutamol 
sulphate and DSCG increased with respect to humidity, while TAA 
decreased. It is suggested that the separation energy ‘cohesion profiles’ can 
be attributed to the physico-chemical and physico-mechanical properties of 
each specific drug.  These factors will be discussed in more detail in Chapter 
6.  
 
In addition, a clear relationship between separation energy distribution and 
surface roughness was observed. This was not unexpected, however as 
large variations in contact area between the micronised drugs and/or 
compacted surfaces exist, which potentially influences cohesion. Conducting 
separation energy measurements on ‘atomically smooth’ crystals of the 
respective drugs subsequently proved this hypothesis.  
 
It is important to note, however, that such measurements are undertaken 
between individual drug probes and model drug surfaces and therefore can 
not be directly related to the complex dynamics that exist during the 
aerosolisation process. Although such observations are fundamentally 
interesting, they require perspective. For dry powder inhaler formulations, 
such large variations in cohesion profile may directly influence aerosolisation 
performance, and subsequently have direct impact on the patient. Since 
environmental conditions in the ‘real world’ are not kept constant, and factors 
such as humidity cannot be controlled, it would be interesting to corroborate 
the AFM cohesion profiles with aerosolisation performance from a DPI. 
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It has become clear, through bulk and AFM measurements, that the influence 
of humidity will play an important role in the particle-particle interactions in a 
dry powder inhaler. However, It is important to note that such measurements 
are generally taken out of context and can therefore not be directly related to 
the complex dynamics that exist during the aerosolisation process. As a 
function of this, an investigation was undertaken to correlate the bulk 
(Chapter 3) and individual drug particle measurements (Chapter 4) with the 
in-vitro aerosolisation performance from a dry powder inhaler. 
 
Studies investigating the influence of humidity on drug aerosolisation 
performance have been conducted in the past, but have generally focused on 
drug-carrier interactions or short exposure times. In addition, these previous 
studies have been conducted by a series of research establishments and 
therefore were not standardised to allow direct comparison. However, a brief 
description of the most relevant investigations is given below. 
 
Recent investigations (Jashnani et al 1995, Jashnani and Byron 1996) have 
shown that storage of a variety of micronised salbutamol salts in relatively 
high humidities for short periods (3-60 mins) resulted in an apparent 
decrease in the relative amount of fine particle fraction (<6.4 µm).  
Additionally, studies describing the relationship between drug aerosolisation 
and humidity reported similar effects for DSCG, (Hindle and Makinen 1996, 
Braun et al 1996). However, these investigations concentrated on the 
aerosolisation of DSCG from larger carrier materials and therefore were not 





The in-vitro aerosolisation investigations of each pure micronised drug was 
conducted during storage inside an environmental humidity test chamber. In 
contrast to previously reported studies (Jashnani et al 1995, Jashnani and 
Byron 1996, Hindle and Makinen 1996, Braun et al 1996), this study focused 
on the investigation of pure drug-drug interactions after relatively long 
storage times (12 hours) at a variety of specific humidities. 
  
Aerosolisation efficiency of each drug at each specific humidity was 
measured using a twin stage impinger (TSI) that separates the drug by 
effective mass median aerodynamic diameter (6.4 µm at a flow rate of 60 
L.min-1 being equivalent to the fine particle fraction). Drug recovered from 
each stage of the TSI and inhaler components was determined by high 
performance liquid chromatography (HPLC).  
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5.2 QUANTIFICATION OF DRUG CONTENT BY HPLC. 
 
5.2.1 Materials and Methods. 
 
The drug concentrations collected from the various components and TSI 
sampling stages during the in-vitro studies were analysed by reverse phase 
HPLC. In simple terms the HPLC operates by separating organic compounds 
by their relative affinity for the solid phase. Chemicals used for the HPLC 
determination of drug content, collected from the TSI sampling stages, are 
given in Table 5.2.1. 
 
The HPLC used was a Waters Alliance unit (Waters, UK).  Briefly, the system 
comprised of a 2690 separations module, (containing a temperature-
controlled autosampler, variable injection sample syringe, four-channel 
gradient pump and column oven) and a 486 tunable absorbance UV 
spectrophotometer.  Data were recorded and integrated using waters 
millennium software. Details of the experimental set-up for each of the five 
micronised drugs is summarised in Table 5.2.2. 
 
Material Manufacturer 
Acetonitrile (HiPerSolv Far UV grade for HPLC) BDH, Poole, UK 
Ammonium acetate (HiPerSolv for HPLC) BDH, Poole, UK 




orthophosphoric acid (analytical grade) 
Fisher scientific, 
Leicestershire, UK 
Potassium dihydrogen orthophosphate – 
(HiPerSolv for HPLC) 
BDH, Poole, UK 
Water (purified through Millipore RiO5 and milliqQplus – 
at 18.5) 
Millipore, Watford, UK 
 











5 µm packing, 25 
cm x 0.32 cm id 
*Hypersil 5ODS, 5 
µm packing, 10 cm 
x 0.5 cm id 
*Hypersil 5ODS-2 
5 µm packing, 10 
cm x 0.46 cm id 
Column Oven 
Temperature (°C) 
40°C 45°C 40°C 










25°C 25°C 25°C 
Injection Volume (µl) 100 µl 100 µl 100 µl 
Detector Wavelength 
(nm) 
223 nm 254 nm 239 nm 
Retention Time 
(minutes) 
4.5 ~ mins 2.5 ~ mins 4 ~ mins 
*Phenomenex, Cheshire, UK 
 
Table 5.2.2. HPLC experimental set-up and instrument settings for the 
micronised drug substances. 
 
Drug was recovered or diluted in a suitable wash solution and analysed using 
a drug specific mobile phase. Details of the specific wash solutions and 
mobile phase are given below.   
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5.2.1(a) Preparation of reagents. 
 
Salbutamol sulphate dilution solvent - 0.05 M potassium phosphate buffer. 
Potassium dihydrogen orthophosphate (6.8 g) was added to 950 ml of milliQ 
water. The solution was adjusted to pH 4.5 by drop wise addition of 
orthophosphoric acid and made up to 1000 ml with milliQ water. 
 
Salbutamol sulphate  mobile phase - 8:92% w/w acetonitrile: potassium 
phosphate buffer. 
Salbutamol sulphate dilution solvent (920 ml) was added to 80 ml acetonitrile. 
 
TAA mobile phase and dilution solution – 37:63% w/w acetonitrile: potassium 
phosphate buffer. 
Potasium dihydrogen orthophosphate (3.4 g) (BDH, Poole, UK) was added to 
950 ml of milliQ water. The solution was adjusted to pH 3.0 by drop wise 
addition of orthophosphoric acid and made up to the mark with milliQ water. 
370 ml of acetonitrile was added to 630 ml of the 0.05 M phosphate buffer. 
 
DSCG dilution solvent - 0.05 M sodium phosphate buffer. 
Anhydrous disodium hydrogen orthophosphate (7.01 g) was added to 950 ml 
of milliQ water. The solution was adjusted to pH 7.4 by drop wise addition of 
orthophosphoric acid and made up 1000 ml with milliQ water. 
 
DSCG mobile phase – 21% w/v 0.015 M sodium phosphate buffer, 0.015 M 
potassium dihydrogen phosphate buffer solution. 
Anhydrous disodium hydrogen orthophosphate (2.13 g) and potassium 
dihydrogen orthophosphate (2.04 g) were added to 700 ml of milliQ water. 




5.2.1(b) Preparation of standards. 
 
Standards for each of the micronised drugs were prepared as follows; 
Duplicate stock standard solutions were prepared by accurately weighing 
approximately 25 mg aliquots of material into two 100 ml volumetric flasks. 
Drug in each flask was dissolved in specific dilution solution. Solutions were 
ultrasonicated for not more than 10 minutes to ensure dissolution, left to cool 
to room temperature, and made up to the mark with dilution solvent. 
 
Working standard solutions were prepared by serial dilution of the stock 
standard solutions using calibrated (class A) laboratory pipettes and same 
dilution solution.  A series of working standard with concentrations between 
0.1 µg.ml-1 and 10 µg.ml-1 were prepared for each drug substance. 
  
Duplicate injections of each working standard were analysed by HPLC with a 
blank, containing dilution solution, being sampled before the first injection 
and after the highest standard. System repeatability was investigated by 
conducting six replicate injections of the lowest working standard.  The 












A =  Equation 5.1.1 Accuracy stock solution weighings.  
 
Where A1 is the mean peak area for the lower working standard 1, A2 is the 
mean peak area for the working standard 2 of same dilution, W1 is weight of 
drug added in stock solution 1 and W2 the weight of drug added in stock 
solution 2. A value of between 0.99 and 1.01 was considered accurate. 
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5.2.2 Results and Discussion. 
 
Sample chromatographs for each of the three drugs (low and high 
concentrations) are given in Appendix 5.1. All drugs exhibited single peaks at 
the approximate retention times given in Table 5.2.2. The concentration-
absorbance linear response for salbutamol sulphate, TAA and DSCG was 
investigated through linear regression analysis and is shown in Figure 5.2.1. 
 
Figure 5.2.1.  Linear peak area to concentration response for salbutamol 
sulphate, TAA and DSCG micronised drugs. Linear regression analysis was 
forced through zero.  R2 values of 0.9999, 1.0000 and 1.0000 were recorded 
for salbutamol sulphate, TAA and DSCG, respectively. 
 
Linear regression analysis for each of the five drugs showed R2 values were 
equal to or greater than 0.9999 inferring a direct linear response between 
peak area and concentration over the range ~ 0.1 µg.ml-1 to 10 µg.ml-1. 
Relative standard deviations between six replicate injections for all five drugs 
were less than 0.5% and accuracy (A), between the weight of stock solution 
1 and stock solution 2, for each of the drugs was within the established 
parameters (0.99-1.01). In addition, no interfering peaks were observed in 
any of the initial blanks, and no sample carryover was observed in blanks 
injected after the higher standards. 
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5.3 OPERATION AND SAMPLING OF TWIN STAGE IMPINGER AT 
SPECIFIC HUMIDITIES. 
 
5.3.1 Materials and Methods. 
 
The influence of humidity on the aerosolisation of the micronised drug 
materials was investigated using apparatus A (see Figure 5.3.1), the twin 
stage glass impinger (Copley Scientific, Nottingham, UK). All experiments 
were conducted inside an environmental test chamber (type KBP 6395 F 
Copley Scientific, Nottingham, UK) capable of maintaining an environment of 
10 – 95% RH (± 0.2% RH) at 25°C. 
 
Figure 5.3.1.  Schematic of the twin stage impinger (adapted from the British 
Pharmacopoeia, 2001, Volume II). 
 
The TSI was assembled as represented diagrammatically in Figure 5.3.1 and 
contained 7 ml of dilution solution in stage one and 30 ml dilution solution in 
stage two.  A pump (Model 1423-101Q-Q626X, GAST, Buckinghamshire, 
UK) generated a flow rate through the TSI of 60 L.min-1 (± 2 L.min-1), which 
was calibrated using a micromanometer (model FC012, Furness controls, 
Bexhill, UK) by adjustment of a needle valve flow regulator. Flow rate was set 
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using a dummy DPI, (Turbohaler®, Astra-Draco AB, Lund, Sweden) 
containing no drug, excipients or desiccant, assembled inside a sealed flow 
chamber. 
 
The micronised drugs were stored in open pans in the environmental test 
chamber at the required humidity for 12 hours prior to analysis. 
Approximately 1500 µg of equilibrated drug material was accurately weighed 
into the plastic metering chamber of a modified DPI (Turbohaler®, Astra-
Draco AB, Lund, Sweden) containing no desiccant.  The DPI and assembled 
TSI were equilibrated, at the humidity under investigation, in the 
environmental chamber for 30 minutes prior to analysis. The loaded DPI was 
inserted into a specially constructed mouthpiece and tested at 60 L.min-1 for 
five seconds using the solenoid valve timer. A three second delay in 
activating the timer, after the pump was engaged, was invigilated to allow 
equilibrium of the pump. 
 
A photograph and diagrammatic representation of the sampling apparatus 
assembled inside the humidity test chamber is shown in Figure 5.3.2. 
 
The DPI, mouthpiece adaptor: throat assembly, stage one and stage two 
were thoroughly rinsed into suitable volumetric flask with dilution solvent and 
made up to the mark. Drug content remaining in the DPI device was collected 
by carefully deconstructing the device components and washing separately 
with solvent. The device components were then rinsed with distilled water 
followed by methanol, and dried at 40°C in an oven. The DPI components 
were left to cool, reassembled and re-used. No apparent degradation in 
component parts or device integrity was observed by conducting this 
procedure. A similar water-methanol rinsing procedure was used for the TSI. 
 
All samples were analysed by HPLC using a bracketing standard protocol 
described in Appendix 5.2. For each humidity and drug, TSI investigations 








Figure 5.3.2  (a) Diagrammatic representation of TSI set-up with calibration 























5.3.2 Results and Discussion. 
 
The in-vitro characterisation for aerosolisation of salbutamol sulphate, TAA 
and DSCG was conducted at 15, 30, 45, 60 and 75% RH at 25°C using a 
TSI. The results obtained from the in-vitro investigations are shown in Table 
5.3.1, and are represented as percent remaining in device, percent in TSI 
throat and mouthpiece adaptor, percent in stage one and percent in stage 
two (Hallworth and Westmoreland 1987). 
 
 Humidity Loaded dose (!g) % in DPI % in Throat % in Stage 1 *% in Stage 2 
15 1782 (219) 14.8 (5.5) 10.7 (3.2) 62.0 (10.3) 12.5 (3.4) 
30 1777 (86) 17.9 (3.6) 10.4 (1.1) 57.3 (6.8) 14.4 (2.7) 
45 1365 (102) 26.9 (3.5) 11.8 (1.5) 47.9 (9.3) 13.3 (1.5) 













75 1637 (438) 87.4 (10.9) 2.0 (2.5) 7.9 (9.9) 2.7 (3.7) 
15 1446 (82) 31.5 (3.3) 30.2 (3.2) 32.3 (1.1) 6.0 (1.9) 
30 1630 (155) 23.2 (5.0) 34.2 (7.1) 34.6 (4.9) 7.9 (0.6) 
45 1585 (161) 21.5 (5.6) 25.1(1.0) 45.1 (3.7) 8.3 (0.9) 





75 1444 (256) 21.8 (6.2) 23.9 (6.8) 41.9 (14.9) 12.3 (3.5) 
15 1274 (251) 16.3 (0.4) 34.8 (6.0) 18.9 (7.1) 29.2 (9.0) 
30 1517 (249) 36.2 (11.1) 17.0 (9.6) 21.8 (18.4) 23.0 (5.7) 
45 1445 (203) 39.7 (11.5) 19.9 (12.9) 20.0 (6.5) 17.3 (7.4) 






75 1662 (137) 92.1 (10.2) 1.1 (1.8) 2.1 (1.8) 0.1 (0.0) 
 
Table 5.3a. Influence of humidity on the aerosolisation performance of 
salbutamol sulphate, TAA and DSCG.* Where stage 2 represents a MMAD 
<6.4µm.  
 
It was considered that the most relevant descriptors for drug aerosolisation 
were the percentage delivered dose (total dose emitted from the DPI as a 
percentage of the loaded dose) and the fine particle fraction (stage 2 of the 
TSI, <6.4 µm) of the loaded dose (FPFLD). It is important to note, however, 
that the fine particle fraction is commonly determined as the dose collected 
from stage 2 as a percentage of the delivered dose and not of the loaded 
dose. However, in cases where large deviations in delivered dose occur (i.e. 
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where the delivered dose becomes very small), this standard method of 
determination may lead to exaggerated FPF values. 
 
The aerosolisation of all three micronised drugs was significantly affected by 
variations in humidity (ANOVA, p<0.05), and can be seen graphically in 




Figure 5.3.3 Drug distribution of aerosolised (a) salbutamol sulphate, (b) 
TAA and (c) DSCG as a function of humidity. Stage 1 includes throat and 





Large standard deviations in the stage recoveries of the TSI can be attributed 
to a non-optimised formulation containing ‘as supplied’ micronised drug 
particles only. 
 
Increased humidity had the greatest impact on the aerosolisation efficiency of 
DSCG, with the mean delivered dose falling from 82% at 15% RH to 3% at 
75% RH. The data in Table 5.3.1 suggest that there is a significant decrease 
(ANOVA, p<0.05) in both the delivered dose and the stage two recoveries at 
higher humidity levels. In order to compare the significance of this 
observation a Fisher pair wise analysis (p<0.05) was performed for stage two 
recoveries at paired humidities. No significant differences were observed at 
paired humidities 15 - 3 0, 30 - 45, and 60 - 75% RH, however, a significant 
difference between 45 - 60% RH and all remaining unpaired combinations 
was observed, suggesting a change over the whole humidity range with the 
greatest impact on fine particle aerosolisation (<6.4 µm) acting between the 
humidities 45 and 60% RH. 
 
A plot of FPFLD against humidity, presented in Figure 5.3.4 suggests a 
decrease in mean FPFLD of DSCG, between 15 and 45% RH. This may be 
attributed to the relative uptake (1.6% w/w) in water across the same range 
(Chapter 3). It is also important to note that the FPFLD of DSCG across the 
range 15 to 45% RH was greater than that of both salbutamol sulphate and 
TAA in all cases. This may be due to a higher density (1.604 g.cm-3) and 
particle size (5.44 µm) of DSCG (Chapter 2), as the forces acting in a 
turbulent airstream to break up agglomerates will be directly related to 
particle mass.  
 
An increase in humidity from 45 to 60% RH resulted in a large statistically 
significant decrease in FPFLD to such an extent that only 1.2% (±1.0) of the 
loaded dose was deposited in stage two of the TSI. Again, this large 
decrease in aerosolisation performance could possibly be attributed to a 
large increase (3.7% w/w) in moisture uptake at 60% RH (Chapter 3). An 
increase in the humidity from 60 to 75% RH resulted in a further increase 
(3% w/w) in moisture sorption, of similar magnitude as for the transition from 
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45 to 60% RH, this was coupled with a decrease in deposition to all stages of 
the TSI, with 92.1% (±10.2) of the loaded dose remaining in the DPI, 
effectively terminating powder aerosolisation.  
 
 
Figure  5.3.4  Influence of humidity on the fine particle fraction (MMAD 
< 6.4 µm) of salbutamol sulphate, TAA and DSCG. Error bars indicate 
standard deviations. Lines between points are for clarification purposes only. 
 
The relationship between increased humidity and decreased aerosolisation 
performance of DSCG is most likely attributed to the hygroscopic nature of 
the powder, as water is rapidly absorbed into the crystal lattice at a specific 
humidity until it forms an equilibrium with the surrounding environment (Cox 
et al 1971). The presence of such a dynamic equilibrium can only promote 
the condensation of water between the capillaries of the powder particulates, 
thus increasing the interparticulate forces whilst decreasing the 
aerosolisation efficiency. 
 
A significant decrease in the aerosolisation efficiency of salbutamol sulphate 
at higher humidities was also observed (ANOVA, p<0.05), However, Fisher 
pair wise analysis (p<0.05) of both the delivered and stage two deposition 
showed this to be significant between 60 and 75% RH only. Moisture sorption 
profiles (Chapter 3), of the salbutamol sulphate showed little increase in 
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water across the range 15 to 75% RH with a total water content of 0.2% w/w, 
at 75% RH in comparison to 15.8% w/w (±0.4) moisture for the DSCG over the 
same range. These observations suggest that water is being appreciably 
adsorbed onto the crystal surface of salbutamol sulphate making the rapid 
condensation of water between capillaries only likely when the humidity 
approaches saturation (Schubert 1984). 
 
The FPFLD of TAA collected at each humidity shown in Figure 5.3.4. In 
contrast to DSCG and salbutamol sulphate, TAA exhibited a small but 
statistically significant (ANOVA, p<0.05) increase in FPF across the humidity 
range 15 to 75% RH. Statistical analysis of the mean percentage delivered 
dose showed no significant difference across the humidity range, therefore, 
suggesting that the variation in aerosolisation efficiency was related to 
particle-particle interactions. The improved aerosolisation efficiency of TAA at 
higher humidities may be attributed to the dissipation of triboelectrification 
induced surface charges. Such charges may be a consequence of the 
irregular plate-like structure of TAA (Chapter 2), facilitating increased particle-
particle contact area. A 1% w/w increase in moisture content of TAA between 
11 and 75% RH, would almost certainly allow the mobilisation of electrons on 
the particulate surfaces leading to possible charge dissipation. This possibly 




5.4 GENERAL DISCUSSION AND CONCLUSIONS: IN-VITRO STUDIES. 
 
The in-vitro investigation has shown the three micronised drug materials to 
have significantly different aerosolisation profiles when exposed to, and 
aerosolised in different environmental humidities. The relationship between 
humidity and aerosolisation of micronised material can be attributed to the 
balance of forces acting between the individual particulates, the proportion of 
each being related to the physical and chemical properties of the material.   
 
In general terms, the fine particle fraction profiles for salbutamol sulphate 
TAA and DSCG correlated well with the particle-particle ‘cohesion’ separation 
energy measurements conducted by AFM (Chapter 4). For example, an 
increase in humidity resulted in a decreased fine FPFLD for salbutamol 
sulphate and DSCG. While in comparison; the AFM separation values 
increased suggesting increased cohesion between micronised particles at 
higher humidity. Furthermore, the small but significant increase in FPFLD for 
TAA at increased humidities correlated well with decrease in AFM measured 
separation energies, suggesting the micronised material to be more cohesive 
at low humidity.  
 
It is important to note however, that such in-vitro measurements are 
dependent on a plethora of factors that would not be measurable using 
fundamental studies such as AFM. For example, the airflow used to disperse 
the micronised material is turbulent, and therefore would induce 
unpredictable angular velocities on the drug (resulting in frictional and 
angular forces), whereas AFM particle interactions were conducted 
perpendicular to the adhesion plane. Additionally the micronised material in 
the in-vitro investigation may only be partially agglomerated and will have 
unpredictable particle-particle and particle-device component contact areas.  
 
Consequently, such constant variables may lead to disparities between the 
observed in-vitro performance and AFM measurements. 
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6 SUMMARY, CONCLUSIONS AND FURTHER WORK. 
 
6.1     INTRODUCTION. 
 
The degree to which particle-particle interactions dominate in a 
pharmaceutical system will be dependent on both the particulate size and the 
solid dosage form used. When considering DPI systems (which target 
delivery of <5 µm particulates to the respiratory tract), the magnitude of the 
adhesion or cohesion forces will be critical for both the interactive mechanism 
and drug liberation during aerosolisation. 
 
Of particular interest was drug cohesion in DPI systems; as such interactions 
will be critical during the aerosolisation process. Three micronised drugs 
were chosen as models for investigation (salbutamol sulphate, TAA and 
DSCG), as they had similar surface area, size and were directly applicable to 
inhalation therapy. 
 
One of the initial goals of the study was to develop the AFM colloid probe 
technique for the fundamental measurement of interactive mechanisms 
between micronised drug particles. Of particular interest was the influence of 
humidity on particle cohesion, since such a variable environmental factor can 
have direct influence on the balance of interparticulate forces. In addition, the 
AFM investigations were conducted along side a series of bulk techniques 
that allowed prediction of the drug cohesion profile. Finally, a series of in vitro 
studies were conducted to allow comparison of the AFM colloid probe 
investigations with aersolisation efficiency. 
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6.2 COMPARATIVE ANALYSIS OF THE THREE MICRONISED DRUGS. 
 
Atomic force microscopy studies of three micronised drugs indicated 
significant differences in the cohesion properties, particularly with respect to 
humidity. In general, the cohesive force (and energy) of salbutamol sulphate 
and DSCG increased with respect to humidity (15-75% RH), while a 
decrease was observed for TAA. In order to conduct such cohesion 
measurements, fixed substrates were required. Three techniques were 
employed for the production of immobilised drug substrates: polymer 
mounting, direct compression and crystallisation. As expected, the drug 
substrates had very different physical characteristics and thus allowed some 
insight into the influence of roughness on separation energy distributions. It is 
important to note however, the rank consistency in cohesion profile with 
respect to relative humidity, remained consistent. 
 
Normalised data for all the cohesion separation measurements (conducted 
by AFM) plotted with the aerosolisation efficiency (FPFLD, determined from in 
vitro investigation) are shown in Figure 6.2.1. In general, the increase or 
decrease in cohesion separation energy as a function of relative humidity, 
between the different substrates showed good correlation. However, 
significant differences did exist (ANOVA p<0.05). For example, in all cases 
the compacted surfaces had a greater impact on separation energy at higher 
humidities (60-75% RH) than the re-crystallised substrates. This may be 
attributed to the variation in surface roughness of each substrate. For 
example, compact and individual polymer mounted particulates had irregular 
surface morphologies, which would promote condensation of water at higher 
humidities. Subsequently, capillary forces and or electrostatic dissipation 








Another issue to consider is the variation in crystal structure. The compacted 
surfaces and individual polymer mounted drug particles will have, to some 
extent, a random orientation of molecules present on the surface due to the 
micronisation process. Although comminution or compressive forces will 
cause fractures along specific planes of a crystal, it is still envisaged that 
there would be a significant number of randomly oriented molecules present. 
Indeed, it has been well documented that micronisation can induce large 
quantities of amorphous material in such systems (Ward and Schultz 1995). 
However, analysis of the water sorption isotherms of each micronised drug 
indicated no characteristic mass loss that would indicate such amorphous 
nature. This observation may be attributed to the storage history of the 
materials used  (approximately 40-60% RH for a two years prior to study). 
However, it is important to note that techniques such as DVS are limited to 
around 1% amorphous content determination, and therefore amorphous 
content in such systems cannot be ruled out. 
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Figure 6.2.1  Normalised AFM colloid probe data plotted with in vitro 





Essentially, the chemical structure of a specific drug will underpin the 
cohesion properties of a DPI system, and when combined with knowledge of 
the crystal structure, may provide a means of explaining why such large 
variations in cohesion profile exist between similarly sized drug particulates. 
 
For example, consider the chemical structure of the model drugs investigated 
here (Figure 2.1.1). Salbutamol sulphate contains two salbutamol groups for 
each sulphate group and thus forms a relatively neutral charged system. In 
comparison, the chemical structure for TAA will result in a polar distribution 
across the molecule (Figure 6.2.2), with the ketone group on the first ring 
being particularly susceptible to protonation.  
 
 
Figure 6.2.2 computer simulation of the electrostatic potential across a TAA 
molecule. Where red, green and red areas correspond to negative, neutral 
and positive polarities. 
 
Although the crystal structure of TAA has not been documented, it would be 
reasonable to assume the molecule would align, in a linear fashion, to 
minimise such polarity. Subsequently it is envisaged that a polarity would 




If this were the case, it may explain the long-range electrostatic forces and 
subsequent high cohesion at low humidity (as observed by AFM). 
Furthermore, the presence of such groups on the surface of the micronised 
material may explain both the relatively high moisture sorption values. For 
example, if polar groups were present across the TAA crystal surface, water 
molecules present in the gas phase would align on the surface due to their 
respective dipoles. Consequently the projected surface area for the water 
molecule would decrease, allowing greater sights at equivalent humidity. In 
addition, the assumption of such polar interactions may explain the increased 
basic contribution to surface free energy measured by IGC (in comparison to 
salbutamol sulphate). 
 
There is no doubt that DSCG is a polar molecule, however, long-range 
electrostatic forces were not observed. Again such observations were 
expected. As previously discussed, DSCG is an interstitial solid held together 
by water molecules. Even at relatively low humidities (15% RH), a large 
percentage of water molecules will still be present, thus making the build up 
of charge unlikely (due to dissipation).  
 
Clearly, the relationship between such physico-chemical properties and the 
aerosolisation behaviour of micronised drugs warrants further study. The 
computation of both chemical and crystal structure information would provide 
invaluable when combined with fundamental measurements as conducted 
here.   
 
However, of primary interest here was the prediction of aersolisation 
performance through direct and fundamental measurement. Indeed, by 
comparison of the normalised AFM separation energy data with the in vitro 
FPFLD a clear correlation can be observed (Figure 6.2.1). Effectively, the 
FPFLD mirrors the separation energy values as a function of humidity. This is 
to be expected, as increased separation energy would result in increased 






Variations in the cohesion properties of micronised drugs may be attributed 
to the balance of interparticulate forces that exist within the respective 
systems. Clearly, such a balance will be dependent upon a multitude of 
factors including, chemistry, crystal structure and surface morphology. For 
dry powder inhalation systems the balance of such forces are critical as 
particulates of micron size (<5 µm) must be aerosolised and delivered to the 
respiratory tract. Subsequently, the understanding and measurement of such 
interactions is of great interest. 
 
Although such studies can be undertaken using conventional in vitro 
techniques, they often prove time consuming. In comparison the AFM, if used 
in the early stages of development, may provide as an invaluable tool for the 
rapid screening of formulation components.  
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6.4 RECOMMENDED FURTHER WORK. 
 
Although the techniques used within this study have proven useful in 
predicting the aerosolisation behaviour of micronised drug particulates, many 
avenues of investigation could be the subject of further work. 
 
It has been shown that the controlled crystallisation of model substrates is a 
useful technique for determining fundamental separation energy 
measurements. The natural progression of this methodology would be to 
model the specific groups present on the surface and apply this knowledge to 
particle-particle adhesion. Furthermore, knowledge of the drug probe 
geometry and surface chemistry would prove invaluable when modelling 
adhesion forces. This could be achieved by controlled crystallisation of the 
drug probes, or the application of novel characterisation techniques to 
existing micronised drug probes. 
 
Finally, it would be interesting to apply such techniques to the entire DPI 
system. Investigation into the physico-mechanical and physico-chemical 
properties of device components, carrier systems and ternary agents would 
provide invaluable information that may predict the performance and stability 
of DPI systems.  
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APPENDICES FOR CHAPTER 1. 
 
A 1.1 Determination of Salbutamol Sulphate Adhesion on Model 




The centrifugal particle detachment method (CPD) was assessed as a 
possible tool for the determination of individual particle interactions. A 
standardised method, developed by Clarke et al (2002), was utilized to 
deposit uniform quantities of drug, of a specific size range, onto model 
substrates prior to study. In this case, the resolution of the technique was 
determined by the quantity of remaining drug on the substrates post 
centrifugation. 
 
Materials and Methods. 
 
The CPD method, developed by Clarke et al (2002) was utilized for the 
determination of drug detachment forces. A brief overview of the 
methodology is given below. 
  
Samples of salbutamol sulphate (approximately 5 mg) were aerosolised from 
a DPI (Spiros, Dura Pharmaceuticals, California, USA) into an Anderson 
cascade impactor (ACI, Apparatus 2, British Pharmacopoeia) at 28.3 L.min-1 
flow rate. Samples were collected from stage 2 (particle size range 4.7 - 5.8 
µm), on aluminium discs (that had been placed around the rim of the 
upturned stage plate, as to maintain an equivalent plate to jet distance). 
 
                                            
*
 Work conducted during an invitation to the School of Pharmacy (2000), Virginia 
Commonwealth University, Richmond, USA). 
 141 
The aluminium sample disks, containing drug deposits, were placed in a 
centrifuge tube assembly, with the drug-substrate surface facing the direction 
of angular velocity. The ultracentrifuge used throughout was a Fullerton L8-
60M (Fullerton, California, USA), with a swinging basket rotor (SW 41 Ti 
Fullerton, California, USA). This allowed the centrifugal force to act at right 
angles to the substrate, and thus eliminated frictional considerations. 
 
The aluminium discs, containing drug deposits, were exposed to rotational 
speeds of 10,000, 20,000 30,000, 35,000 and 40,000 rev.min-1. Considering 
a substrate-pivot radius of 0.0674 m the relative centrifugal force (RCF) can 






=    Equation A1.1 RCF calculation. 
 
Where ! is the angular velocity (rads.s-1), r the radius (m) and g gravity. This 
gave relative accelerations of 7542 to 120673 X g. 
 
After centrifugation at a specific velocity, the substrate discs and sample 
chamber were washed into separate volumetrics with HPLC mobile phase 
(0.1% ammonium acetate solution in 30:70 v/v methanol water). Samples 
were analysed by HPLC using the following parameters: ODS C-18 
spherisorb column (Alltech Associates, Illinois, USA), flow rate - 0.8 ml.min-1, 
RF 551 Flouresence detector (Shimadzu Corp., Japan), excitation and 
emission wavelengths 276 nm and 609 nm, respectively. 
 
Results and Discussion. 
 
Salbutamol sulphate, aerosolised using the Spiros DPI, formed discrete 
deposits on the aluminium sample discs (between 8 and 10 deposits per 
disc). Analysis of the total recovered drug (substrate disc plus sample 
chamber) indicated a mean deposit mass of 1490.4 ng ± 258.6 ng across all 
experiments and centrifuge velocities. In addition, ANOVA one way and 
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Fisher pair wise analysis indicated no significant difference (p<0.05) between 
the deposits used at different centrifuge velocities. 
  
Analysis of the percentage drug remaining on the aluminium substrates was 
calculated as a function of the total recovered drug concentration. and is 
shown graphically in Figure A.1. 
  
Figure A 1.  Percentage drug remaining on aluminium substrate as a 
function of relative centrifugal acceleration. 
 
At a maximum centrifugal acceleration of 120673 g (40,000 rev.min-1), 17.2% 
± 4.7% of the drug remained on the aluminium substrate. Subsequent 
observation of the substrate indicated this to be a layer of micronised 
particles, with the majority of particles being removed as a mound. It is 
therefore purposed (in this case), the drug cohesion forces to be weaker than 
the drug-substrate forces. 
 
Since, the measurement of cohesion forces would prove difficult using the 
CPD method (a primary goal of this research) it was consequently decided 




A 1.2 Determination of Salbutamol Sulphate Adhesion Using the Re-
Entrainment Tube Method. 
 
Materials and Methods. 
 
Figure A 1.2 shows a schematic of the custom-built entrainment apparatus, 
consisting of a 0.005 m x 0.005 m square glass duct 1.5 m in length. A 
sample test section was positioned 1 m downstream from the air inlet duct, 
and consisted of a removable substrate holder and viewing screen, that when 
positioned, were flush with the duct as not to affect flow. In addition, a 
calibrated glass flow meter (0-200 L.min-1) was used to measure the airflow, 
generated by two rotary vein pumps (connected in parallel to the entrainment 
tube). Samples of salbutamol sulphate, were deposited on either aluminium, 
or glass substrates by sieving through a 45 µm aperture sieve (found to 
remove large agglomerates). 
 
Drug particle removal was recorded by a CCD video reflection microscope 
(Digital Instruments, Cambridge, UK), with a 500 X long working distance 
lens, connected to a PC with associated software (Optimas 5.2, Media 
Cybernetics, Rochester, New York, USA).  
 














Sealed sampling port with powder 
mounted on sample substrate
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Results and Discussion. 
 
Using two pumps in parallel, linear flow velocities of up to 133 m.s-1 could be 
achieved (calculated from Bernoullis theorem; V = Q/A, where V is velocity, 
Q is flow rate and A the duct cross sectional area). 
 
In general, only agglomerated material was removed (>10 µm). Such an 
observation was expected as the relative linear acceleration acting on the 
individual particles resulted in an applied force less than the force of 
adhesion (three orders of magnitude). However, it is interesting to note, many 
small agglomerates (with diameters that would result in removal forces less 
than the adhesion force (~1x10-3 m)) were removed. 
 
An explanation for the removal of small agglomerates is most likely due to a 
series of factors. For example, the agglomerates will have a relatively small 
particulate substrate contact area and therefore low adhesion force. In 
addition, at relatively high flow rates, the turbulence produced would result in 
a complicated and difficult array of forces. Turbulence can be described by 






=Re      Equation A 1.2 Reynolds number. 
Where hc is the channel diameter, , the gas density, and µ the gas viscosity  
By plotting the Reynolds number against flow rate, the degree of turbulence 
can be assessed. 
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A 1.2(II) influence of flow rate and velocity on Reynolds number (for a air 
duct with 0.005 m diameter). 
 
For airflow through pipes, a Reynolds number less than 2000 is considered 
laminar, while a Reynolds number greater than 4000 is considered turbulent 
(Hinds 1999). Thus, for an entrainment tube with a diameter of 0.005 m a 
flow velocity greater than approximately 13 m.s-1 (20 L.min-1) would result in 
turbulent flow. 
 
Since a turbulent flow would result in many angular forces acting on adhered 
particles, the fundamental measurement of removal forces would be difficult. 
Furthermore, as the majority of micronised particles were not removed at the 




APPENDICES FOR CHAPTER 2. 
 
A 2.1 Optimum De-aggregation Time for Particle Size Measurement. 
 
Approximately 100 mg of powder was suspended in a 0.1% w/w lecithin 
cyclohexane solution and measured for mode diameter (µm) (Malvern 
Mastersizer X, Malvern Instruments, Worcs, UK) using a small volume 
sample dispersion cell (MSX1, Malvern Instruments, Worcs, UK). Samples 
were ultra-sonicated (FS 300B ultra-sonicator, Decon Laboratories Ltd, 
Sussex, UK) for cumulative periods between measurements. All 
measurements were determined in triplicate. 
 
Time (Seconds) Salbutamol sulphate TAA DSCG 
0 24.3 ± 14.33 6.6 ± 0.50 2.4 ± 0.34 
20 5.3 ± 0.03 3.8 ± 0.01 1.7 ± 0.05 
40 4.7 ± 0.16 3.4 ± 0.03 1.5 ± 0.01 
60 4.4 ± 0.11 3.4 ± 0.02 1.5 ± 0.04 
80 4.2 ± 0.07 3.2 ± 0.03 1.5 ± 0.02 
100 4.0  ± 0.04 3.2 ± 0.07 1.4 ± 0.03 
120 3.8 ± 0.05 3.1 ± 0.08 1.4 ± 0.01 
180 3.6 ± 0.07 3.1 ± 0.02 1.4 ± 0.05 
240 3.5 ± 0.06 2.9 ± 0.05 1.4 ± 0.01 
300 3.1 ± 0.07 2.7 ± 0.03 1.4 ± 0.10 
600 2.8 ± 0.17 2.5 ± 0.13 1.4 ± 0.02 
1200 2.9 ± 0.04 2.5 ± 0.03 1.4 ± 0.02 
 
A 2.1 (I) Influence of sonication time on particulate mode diameter (µm), 
at 25°C. 
 
An ultra-sonication time of 5 minutes was determined sufficient to de-
agglomerate the micronised drugs prior to particulate distribution analysis. 
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A 2.2  Particle Size Distributions for the Micronised Drugs. 
 
A 2.2 (I) Particle size distribution for salbutamol sulphate. 
 
 
A 2.2 (II) Particle size distribution for TAA. 
Particle size / !m












































d (0.5) = 4.79 !m
D (4,3) = 5.43 !m
d (0.1) = 0.60 !m
Span = 2.07
d (0.9) = 10.53 !m
Sauter Mean (D [3,2]) = 1.26 !m
Particle size / !m














































d (0.5) = 4.39 !m
D (4,3) = 4.76  !m
d (0.1) = 2.57 !m
Span = 1.12
d (0.9) = 7.48 !m
Sauter Mean (D [3,2]) = 4.76 !m
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A 2.2 (III) Particle size distribution for DSCG. 
Particle size / !m












































d (0.5) = 5.44 !m
D (4,3) = 6.31 !m
d (0.1) = 2.71 !m
Span = 1.55
d (0.9) = 11.12 !m
Sauter Mean (D [3,2]) = 6.31 !m
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APPENDICES FOR CHAPTER 3. 
 
 
A 3.1 Salts for the Control of Relative Humidity. 
 
Static relative humidities were maintained by storing saturated salt solutions 
in tightly sealed containers. In addition, the desiccant, phosphorous 
pentoxide was used to produce a humidity free environment. A summary of 
the saturated salts used is given in table A 3.1(I). 
 
Saturated salt solution. 
Percent relative 
humidity (% RH). 
Phosphorous pentoxide. 0 
Lithium chloride. 11 
Calcium chloride. 29 
Potassium carbonate. 43 
Sodium permanganate. 63 
Sodium chloride. 75 
Potassium chloride. 84 
 
A 3.1(I) Salts used for the preparation of relative humidities. Taken from 




A 3.2 Karl Fischer Equilibrium Moisture Content Determination for the 
Three Micronised Materials after Storage at Various Humidities. 
  
 Equilibrium moisture content (% w/w) 
Humidity (% RH) Salbutamol - 
sulphate 
TAA DSCG 
0 0.11 ± 0.01 0.63 ± 0.06 3.17 ± 0.55 
11 0.12 ±0.01 0.93 ± 0.06 7.40 ± 0.17 
29 0.16 ± 0.01 1.33 ± 0.06 7.90 ± 0.10 
43 0.16 ± 0.01 1.50 ± 0.00 9.13 ± 0.12 
62 0.16 ± 0.02 1.70 ± 0.00 12.83 ± 0.06 
75 0.18 ± 0.01 1.87 ± 0.06 15.80 ± 0.36 
84 0.19 ± 0.03 1.97 ± 0.06 17.17 ± 0.31 
 
A 3.2(I) Equilibrium moisture content for salbutamol sulphate, TAA and 
DSCG measured by Karl Fischer water titration. (Mean ± standard deviation). 
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APPENDICES FOR CHAPTER 4. 
 
A 4.1  Validation of AFM Drug Probe Force Curve Parameters.  
 
A 4.1 (I) Influence of compressive loading (constant compliance region) 
on the separation force and energy to separate a salbutamol sulphate drug 
probe from a mica surface.  
 
 
A 4.1 (II) Influence of scan rate (cycle time) on the separation force and 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Influence of humidity on the cumulative separation energy values for 
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Influence of humidity on the cumulative separation energy values for TAA drug 
probes 2-5 on model compact TAA surfaces.   
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Influence of humidity on the cumulative separation energy values for DSCG 
drug probes 2-5 on model compact DSCG surfaces.   
Tip 2 Tip 3
Tip 4 Tip 5
1x102 1x103        1x104    1x105  1x106 1x102 1x103     1x104        1x105  1x106




Influence of humidity on the GSD for (a) salbutamol sulphate drug probes on 
model compact salbutamol sulphate surfaces (b) TAA drug probes on TAA 
compact model surfaces and (c) DSCG drug probes on DSCG compact 







Influence of humidity on the cumulative separation energy values for (a) 
salbutamol sulphate drug probes two and three interactions with re-
crystallised salbutamol sulphate surfaces, (b) TAA drug probe two and three 
interactions with re-crystallised TAA surfaces and (c) DSCG drug probe two 
and three interactions with re-crystallised DSCG surfaces (taken at 15, 30, 
45, 60 and 75% RH). 
 
1x102 1x103        1x104    1x105  1x106 1x102 1x103        1x104    1x105  1x106
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APPENDICES FOR CHAPTER 5. 
 
Appendix 5.1 Sample Chromatographs of Salbutamol Sulphate, 
TAA and DSCG. 
 
 
A 5.1 (I)  HPLC chromatogram for salbutamol sulphate (a) low working 







A 5.1 (II) HPLC chromatogram for TAA (a) low working standard and (b) 










A 5.1 (III) HPLC chromatogram for DSCG (a) low working standard and 




Appendix 5.2 Calculation of Bracketing Standards for HPLC. 
 
 
Calculation of sample concentration in HPLC samples using the bracketing 
standards method. 
 
Two stock standard solutions were prepared from separate weighings, and 
were subsequently diluted to give standard concentrations either side of the 
expected sample concentrations. Both standard and sample concentrations 
were prepared/diluted to fit within the validated linearity region (Chapter 5). 
 
Samples (SAMP) were run bracketed between two standards (std) i.e. 
 
STD1, SAMP, SAMP, STD2, SAMP, SAMP, STD1, SAMP……….. 
  
Each sample and standard was run twice and the mean peak area 
calculated. Sample concentration was calculated using response factors 
obtained from the adjoining standards.  
 
fsampsampsamp RDAC =  
 
Where Cs is sample concentration Asamp is sample absorbance Dsamp dilution 
factor and Rf response factor 
 







R =  
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